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ABSTRACT 
INTERACTION OF FERRITIN WITH TRANSITION  
METAL IONS AND CHELATES 
 
Lei Zhang 
Dr. Ivan J. Dmochowski 
In this thesis, interaction of ferritin with transition metal ions and chelates is studied. First, 
a simple method for synthesizing gold nanoparticles stabilized by horse spleen apoferritin 
(HSAF) was reported using NaBH4 or 3-(N-morpholino)propanesulfonic acid (MOPS) as 
the reducing agent. The average particle diameters were 3.6 and 15.4 nm for NaBH4-
reduced and MOPS-reduced Au-HSAF, respectively. NaBH4-reduced Au-HSAF was 
much more effective than MOPS-reduced Au-HSAF in catalyzing the reduction of 4-
nitrophenol by NaBH4, based on the greater accessibility of the NaBH4-reduced gold 
particle to the substrate. Methods for studying ferritin-gold nanoparticle assemblies may 
be readily applied to other protein-metal colloid systems. Second, the binding interactions 
between HSAF and three recombinant apoferritins and two commonly employed 
gadolinium magnetic resonance imaging (MRI) contrast agents were investigated. The 
anionic Gd(DTPA)2- complex was undetectable in apoferritin solutions after dialysis, 
indicating little protein-binding interaction. However, the non-ionic Gd(DTPA-BMA) 
complex bound to all apoferritins tested, producing remarkable relaxivity enhancements 
as well as inhibition of iron mineralization. Serum ferritin binding and dysregulation of 
iron mineralization may have medical significance, particularly in patients with impaired 
kidney function.   
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Chapter 1: Introduction 
 
1. Prologue 
In the history of human civilization, curing diseases and common ailments by means of 
herbal remedies is among the earliest endeavors that might be classified as medical 
science. The ancient Greeks and Chinese actively sought out these gifts of nature, using 
all manner of herbs to heal sickness and boost health.† One widely known example is tea. 
The health benefits of tea have been examined ever since the first infusions of Camellia 
sinensis almost 5000 years ago.1 Modern research has revealed an inverse correlation 
between green tea consumption and levels of serum markers including ferritin, implying 
that green tea may act protectively against various cardiovascular diseases.2 More 
recently, researchers at Cornell studied the effect of tea polyphenols on iron uptake by 
ferritin in Caco-2 cells suggesting possible interactions between ferritin and tea 
polyphenols, which could affect iron uptake.3 These are vivid examples showing how 
experiential learning is linked to and explained by modern science. Now it is time to start 
our own research journey, which is also relevant to the star molecule ferritin. In this 
thesis, we use ferritin as a nanoscale biomolecular platform for complexation of particles 
and molecules. 
 
________________________________________________________________________ 
† I have developed a natural interest in this field, probably because my late grandfather was a 
doctor in the Hospital of Shandong University of Traditional Chinese Medicine (In Memoriam: 
http://wh.sdzydfy.com/book4/2008321919455353.htm#wps). 
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2. Ferritin: Structure and Function 
Ferritin was first discovered in 1937 by the French scientist Laufberger, who isolated a 
new protein from horse spleen that contained up to 23% by dry weight of iron.4 Since 
then, it has been found in most living organisms, such as bacteria, fungi, plants, mollusks, 
insects and vertebrates. Ferritin is synthesized in response to iron; much is now known 
that the interactions of iron-regulatory proteins and iron-responsive elements play a 
pivotal role in controlling iron homeostasis in invertebrates and vertebrates via regulation 
of ferritin gene expression.5 Its universal occurrence as well as its fascinating ability to 
reversibly store and release iron ions to the living cells has attracted the interest of 
researchers worldwide.6-12 
Over the past several years, ferritins have been classified as maxiferritins and 
miniferritins.8,13 These two classes have distinctly different inner and outer diameters, 
and molecular weights: (1) maxiferritins, 12 nm in diameter with 8 nm diameter cavities, 
formed from 24 subunits (MW ≈ 480 kDa); and (2) miniferritins, also called DNA 
protection during starvation proteins, 8 nm in diameter with 5 nm diameter cavities, 
formed from 12 subunits (MW ≈ 240 kDa).14,15 In this thesis, we focus solely on 
maxiferritins, and maxiferritin in this context is always referred to as ferritin. A core of 
hydrous ferric oxide [Fe(III)O∙OH] is stored in the central cavity. Up to 4500 iron atoms 
can be included in the core along with variable amounts of phosphate.16  
Ferritin is an enzyme. It is a good place here to introduce the enzymatic properties of 
ferritin. Published studies relevant to the enzymatic properties of ferritin can be classified 
into two categories: (1) fundamental studies of reactions catalyzed by native ferritins; (2) 
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applications of reactions catalyzed by engineered ferritins. Research relevant to (2) will 
be introduced in Section 3.1 of this chapter. Reactions in (1) can be further classified into 
two sub-categories: (1.1) reactions catalyzed by the ferroxidase centers of ferritin; (1.2) 
reactions catalyzed by the iron core of ferritin. 
The catalytic activity of native ferritins is associated with the H-chain subunits that 
contain the dinuclear ferroxidase center.17-19 At low iron loading (below or equal to that 
required to fill the ferroxidase centers), the dominant reaction can be described by the 
following net equation:20,21 
2Fe2+ + O2 + 4H2O  2FeOOH + H2O2 + 4H+ 
The above oxidation reaction has been shown to proceed via a μ-1,2-peroxodiferric 
intermediate giving a characteristic blue color (λmax = 650 nm),22-25 which subsequently 
decays to a more stable μ-1,2-oxodiferric species with the release of H2O2.26 
When intermediate numbers of iron is added (100~500 Fe2+ per protein), some of the 
hydrogen peroxide produced in the above reaction will be consumed in an Fe2+ oxidation 
reaction:27 
2Fe2+ + H2O2 + 2H2O  2FeOOH + 4H+ 
When large amounts of iron are added (>800 Fe2+ per protein), auto-oxidation 
catalyzed by the growing core surface becomes the dominant reaction:20,27 
4Fe2+ + O2 + 6H2O  4FeOOH + 8H+ 
In (1.2), ferritin plays an important role in the decomposition of noxious derivatives of 
oxygen, thus reducing exposure of cells to potentially damaging species such as peroxide, 
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superoxide, and hydroxyl radical.28 The iron core of ferritin acts as a catalyst in the 
Haber-Weiss reaction which generates the extremely injurious hydroxyl radical.29 
The iron core can be removed by reduction of Fe3+ and chelation of Fe2+.30 Ferritin can 
be reconstituted from apoferritin upon addition of Fe2+ and an oxidizing agent.31 Watt and 
co-workers found that iron loading into ferritin can be stimulated in the presence of 
phosphate and its closely related analogs arsenate, vanadate, and molybdate.32 Cations 
(Li+, Na+, K+, Rb+, Cs+, NH4+) were shown to slow iron loading into ferritin by a general 
positive charge screening effect. Trigonal planar anions do not inhibit iron loading into 
ferritin. Sulfate, iodide, and fluoride were shown to slow the rate of iron loading but the 
same final absorbance is achieved suggesting that the mineral core is unchanged. Here we 
begin this section with the review of the structure and function of apoferritin. 
2.1. Apoferritin 
The apoferritin structure, first reported in 1975, was from horse spleen, which contains 
85% light (L) and 15% heavy (H)-type chains.33-35 Comparative studies of the 
morphology of crystals of apoferritin from mammals and E. coli indicate great similarity 
of packing.36 Horse spleen apoferritin (HSAF) serves as the prototypal apoferritin in this 
thesis due to its commercial availability and natural combination of H- and L-chain 
subunits. HSAF crystallizes readily as a Cd2+ salt, and its crystal structure has been 
reported by several research groups.15,35,37 To date, the highest resolution available for 
HSAF is 1.15 Å (Protein Data Bank ID: 2V2P). Each subunit of HSAF contains 174 
amino acids folded into a bundle of two pairs of α-helixes joined by a long loop (Figure 
1.1). The four long α-helixes are comprised of residues T10-Y36 (A), E45-R72 (B), T92-
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Al19 (C), and P123-V155 (D), respectively, while the fifth shorter helix extends from 
residues A159 to L169 (E). A long loop connecting two helixes contains residues G73-
T91. At each of the eight corners of the HSAF 24-mer cubic unit cell, threefold 
symmetric interactions between three nearest subunits form a channel with highly 
conserved hydrophilic character. The demonstration of various metal-binding sites in 
these channels and the presence of conserved residues, D127 and E130, at the base of the 
channels suggest that the channels could be important for transporting metal in and out of 
the protein.15,34,35 Mutagenesis study of conserved residues inside these channels also 
supported this conclusion.38 Interactions of four subunits form six fourfold symmetric 
channels lined by hydrophobic residues such as L165. Each of these six channels is about 
1.0 nm in diameter at the surface of the molecule, constricts to about 0.7 nm, and then 
widens again to about 1.6 nm near the inner core of the protein.15,34,35 It has been 
suggested that the six fourfold channels provide a pathway for transferring protons during 
iron mineralization.39 
It is noteworthy that metal ion bridging plays an important role in crystallizing certain 
types of ferritins. As mentioned above, HSAF (H / L subunits ≈ 1 : 5) crystallizes as a 
Cd2+ salt; HSAF molecules are linked by double Cd2+ bridges in the crystals. These 
double Cd2+ bridges are situated near the crystal twofold axes formed by pairs of Asp and 
Gln side chains. However, adding Cd2+ to H ferritin results in the formation of 
amorphous precipitates. This is because in all H ferritins, Asp-84 is conserved, whereas 
Gln-86 is replaced by another amino acid, usually Lys. Therefore, in a 1991 Nature paper, 
Lawson et al. replaced the wild-type Lys-86 in human H ferritin (HuHF) with Gln-86, 
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and successfully crystallized it as a Ca2+ salt.17 This eliminates problems that were 
initially encountered with trying to crystallize HuHF and its mutants without substitution 
of the wild-type Lys. More recently, using modern crystallization screening kits, Butts et 
al. successfully crystallized two HuHF mutants that lacked this LysGln point 
mutation.40 But it was determined that adding Ca2+ to the ferritin solution was still 
necessary to achieve crystals. 
2.2. Ferritin assembly 
Ferritin is known to disassemble into subunits at pH 2 and reassemble into the 24-mer 
at pH 7.41 However, this pH-driven disassembly-assembly process often causes loss of 
protein activity due to the near-denaturing conditions at low pH. 
In 2005, Johnson and co-workers reported the crystal structures of a tetrahedral open 
pore ferritin from the hyperthermophilic archaeon Archaeoglobus fulgidus, which 
represents the first structure of a ferritin from an archaeon, or a hyperthermophilic 
organism.42 The exceptional property of this A. fulgidus ferritin (the wild-type protein is 
hereafter abbreviated as T0) is its salt-mediated, fully reversible assembly/disassembly: at 
low salt concentrations, the protein exists as dimers of four-helix bundles. As the salt 
concentration is increased to approximately 600 mM, all of the protein dimers self-
assemble into 24-mers. Swift et al. encapsulated gold nanoparticles within the cavity of 
T0 via particle-directed assembly of T0 subunits in high yield.43 Employing this 
methodology, Appendix 1 of this thesis will present the preparation and characterization 
of a T0 mutant-based streptavidin-biotin complexation system. 
2.3. The iron core 
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Various techniques have been used to study the process of mineral core formation in 
ferritin.44 The most widely used technique, also the one used in Chapter 3 of this thesis, is 
the aerobic oxidative iron uptake assay, or ferroxidase assay, which involves the aerobic 
addition of Fe2+ to a suitably buffered protein solution. This technique relies on the 
measurement of the absorbance increase at 340 to 410 nm, which is associated with the 
formation of a Fe-O mineral whose brown color arises from a O  Fe3+ charge transfer.45 
A major proposal for iron core formation is the crystal growth mechanism described by 
Clegg et al.36 In their proposal, starting with the empty protein shell, incoming Fe2+ is 
oxidized on the inner surface of the protein. These oxidized Fe2+ form polynuclear iron 
clusters which can act as nucleation centers for mineral growth (the nucleation stage). At 
a certain time point one of the clusters becomes the dominant nucleation center and 
growth of the mineral core occurs from this site (the core formation stage). In 2009, by 
using high angle annular dark field STEM, Brown and co-workers performed 3D 
morphological studies of the human hepatic ferritin mineral core and provided new 
insights into the core formation mechanism.46 They found out that during the early stage 
of iron deposition, the sites near the ends of the eight threefold channels are favorable for 
the incoming Fe2+ to be oxidized and mineralized. As this process goes on, more Fe2+ 
enters into ferritin and is further oxidized and mineralized on the surface of any existing 
Fe3+ deposits near the entry channels. With higher iron-filling, a cubic-like core structure 
with eight subunits develops. Oxidation of additional incoming Fe2+ results in the early 
deposited Fe3+ diffusing inwards, which forms closely packed crystalline structures of 
ferrihydrite. 
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Although the mineral core of ferritin was traditionally described as ferrihydrite, more 
recent studies have revealed a polyphasic structure consisting of “classic” ferrihydrite and 
other phases, including a magnetite-like phase.47,48 Gálvez et al. demonstrated that the 
native ferritin iron core consists of a polyphasic structure including ferrihydrite (FeOOH), 
magnetite (Fe3O4), and hematite (α-Fe2O3).49 TEM, SAXS, and XANES findings suggest 
a ferrihydrite-enriched core with a surface predominantly formed by magnetite, and the 
ferrithydrite phase is more labile to chemical reduction and mobilization compared with 
the magnetite phase. As iron was removed from ferritin, the relative amount of 
ferrihydrite fell from ~60% to ~20%, and the percentage of magnetite rose steadily from 
~20% to ~70%. The percentage of hematite remained in the range of ~20% to ~10% 
during this process. These results confirm the heterogeneous structure of the ferritin core. 
It may be noted that certain publications refer the composition of the native ferritin iron 
core as ferrihydrite, magnetite, and maghemite (γ-Fe2O3).50 A better understanding of the 
structural nature of the iron core is beneficial to the extended investigation on the 
formation and complexation of various particles within ferritin. Studies relevant to the 
formation of mineral core of different metals in ferritin will be discussed in the following 
section. 
 
3. Ferritin as the Complexation Host 
Biomolecules, such as DNA51-54 and protein,55-58 have also been developed as host 
templates for constructing nanomaterials toward various applications. Kelley and co-
workers reviewed recent studies that exploit biomolecules as templates and scaffolds for 
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the synthesis and manipulation of inorganic nanomaterials including metals, 
semiconductors, and carbon nanotubes.51 These precedents suggested that imparting a 
more complex structure at the nanoscale, such as core-shell nanoparticles,59 would offer 
significant improvements in the performance of traditional semiconductor devices. 
Matsui reviewed the research progress in the field of self-assembled peptide-based 
nanostructures.58 The application of these molecular self-assemblies of synthetic peptides 
as nanometer-scale building blocks in devices is robust, practical, and affordable due to 
their advantages of reproducibility, large-scale production ability, monodispersity, and 
simpler experimental methods. Overviews of protein cages as multifunctional 
nanoplatforms,60 together with special summaries of research works relevant to the 
nanoparticle synthesis in protein cages,56 the application of thermostable protein cages,61 
the utilization of plant viruses as templates in bionanotechnology,57,62 have been 
presented by various authors. 
My thesis is associated with various topics of using biomolecules as the templates to 
construct complexed systems. Research works in Chapters 2 and 3 and Appendix 1 of 
this thesis are all related to ferritin-based complexation systems. Appendix 2 of this thesis 
will investigate the preparation and properties of a DNA-based streptavidin-biotin 
complexation system. 
There has been a rich literature record of using ferritin as a host platform for 
complexation of particles and molecules. It is interesting to note that Young and Douglas 
proposed in a few recent review articles that the complexation modes of guest molecules 
with the protein host can be classified into three categories: the interior, the interface, and 
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the exterior interactions of the guest species with the host.60-63 All publications in this 
field can be virtually sorted into one of these three categories. A literature survey of 
ferritin complexing with particles and molecules will be given in Chapters 2 and 3 of this 
thesis, respectively. Here in the Introduction, we highlight instead the potential 
applications of ferritin-based complexation systems. 
3.1. Catalysis within the large ferritin central cavity 
The history of performing catalyzed reactions inside the large central chamber of 
ferritin dates back to 2004, when the size-selective olefin hydrogenation reaction 
catalyzed by Pd nanoclusters inside apoferritin was carried out.64 For sample preparation, 
apoferritin was treated with 500 equiv of K2PdCl4 at pH 8.5. The Pd2+ ions were reduced 
by 5 equiv of NaBH4 to yield Pd clusters. Olefin hydrogenation reactions were carried 
out in aqueous solution at 7 °C (pH 7.5) with 30 μM Pd. The hydrogenation turnover 
frequency (TOF = [product (mol)] per Pd atom per hour) for CH2=CHCONH-iPr was 
8.10 times larger than that of CH2=CHCOOH catalyzed by Pd nanoclusters inside 
apoferritin. When catalyzed by pure Pd particles (under the same conditions, but without 
apoferritin), the TOF ratio drastically decreased to 1.25. This result can be explained by 
the observation that it is less favorable to diffuse negatively charged molecules 
(CH2=CHCOO-, Gd(DTPA)2-, etc.) into ferritin than neutral molecules (CH2=CHCONH-
iPr, Gd(DTPA-BMA), etc.). This result is consistent with a previous investigation by 
Chasteen and co-workers, who used EPR spectroscopy and gel permeation 
chromatography to study the molecular diffusion of small nitroxide spin probes (7-9 Å 
diameter) into the ferritin cavity.65,66 They found that the positively charged and neutral 
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probe molecules penetrated the cavity, whereas the negatively charged probe molecules 
did not. An important implication from the above catalytic study is that the ferritin shell 
can be used to control the relative rates of catalytic reactions with different substrates, 
based on size or charge of the substrate. It may be noteworthy the observation by Watt 
and co-workers that chloride anion is transported into ferritin during reduction of the iron 
core.67 This may help us to realize that size is important factor in addition to charge that 
governs whether or not a molecule can be diffused into ferritin. Cl- (from the Watt work), 
CH2=CHCOO- (from the above catalytic work), and 7-9 Å nitroxide (from the Chasteen 
work) are all negatively charged molecules. But their abilities of diffusing into ferritin 
decrease drastically, apparently correlated with size. 
The olefin hydrogenation reaction catalyzed by Au/Pd core-shell nanoparticles inside 
apoferritin was similarly examined.68 The catalytic activity of Pd located on the surface 
of [Au](Pd) can be improved due to the electronic interaction between the Au core and 
the Pd shell, which could provide an uneven distribution of electrons. The Pd in the 
surface layer becomes poorer in electron density than in the Au core, which could make 
Au/Pd core-shell nanoparticles more active than Pd clusters since the substrate olefin 
having a double bond favors the electron-deficient surface.69,70 Most recently, the 
reduction of 4-nitrophenol in the presence of NaBH4 by Au-Ag alloy nanoparticles inside 
HSAF was reported.71 Exponential increase of the rate constant of the reduction was 
observed when increasing the Au content in the Au-Ag alloy. 
Not only metal nanoparticles, but also organometallic compounds can be loaded into 
apoferritin to catalyze reactions in confined spaces. Organometallic chemistry in confined 
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spaces adds a new dimension to traditional surface organometallic chemistry as verified 
by highly efficient nanovessel reactors and quantum-confined materials.72 Performing 
organometallic compound-catalyzed reactions will help us not only understand the 
interaction between proteins and organic molecules, but also find new applications in 
catalytic reactions. Contributions in this field include redox reactions catalyzed by 
ferrocene derivatives,73 the Suzuki coupling reaction catalyzed by Pd(allyl),74 and 
phenylacetylene polymerization reactions catalyzed by Rh(nbd), all inside apoferritin.75 It 
is noteworthy that the binding of these metal chelates inside apoferritin has been studied 
by single-crystal X-ray crystallography. I want to particularly mention the ferrocene 
work,73 because in this study ferrocene interacted noncovalently with the interior of the 
protein. Three monosubstituted ferrocene derivatives (ferrocene carboxylic acid, 1; 
dimethylaminomethylferrocene, 2; 1-dimethylaminoethylferrocene, 3) were loaded into 
recombinant horse L-chain apoferritin. ICP-OES spectroscopy together with protein 
concentration determination revealed that 1.9, 2.4, and 0.8 equiv ferrocene per subunit 
were incorporated into 1-, 2-, and 3-apoferritin, respectively. The number of ferrocene 
per subunit was quite high in all cases, suggesting that there were many weak interactions 
with the ferritin interior. Crystal structures were determined with resolutions of 2.0, 1.6, 
2.0 Å for 1-, 2-, and 3-apoferritin, respectively. The anomalous Fourier difference map 
calculation for 2- and 3-apoferritin showed the existence of a new anomalous peak at the 
twofold symmetry axis of the apoferritin molecule, which located between the 
monomeric subunits of the apoferritin shell. Although the structures of the ferrocene 
derivatives within the protein shell could not be determined, the X-ray analysis indicated 
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the binding of the ferrocenyl amines 2 and 3 at this position. Curiously, a similar 
anomalous peak for 1-apoferritin was not observed; one possible explanation is that the 
negative charge of the carboxylate lowered the propensity of 1 to permeate the ferritin 
protein shell.  
3.2. Therapy 
Systems of organic molecules or inorganic particles trapped inside apoferritin have 
shown promising therapeutic applications. In iron chelation therapy, it is known that 
excessive iron in the human body will accumulate in the liver and other organs, which 
can lead to the damage to tissue and organ.76 Complications associated with elevated iron 
levels can be largely avoided by the use of molecules that can chelate and remove a 
sufficient amount of iron, maintaining the body iron load at a non-toxic level. 
Desferrioxamine B (DFOB) is the current drug for iron chelation therapy used via 
injection. However, DFOB has short plasma half-life and must be administered slowly 
over a period of time to be effective.77,78 One potential strategy then for improving the 
efficacy of DFOB, is to trap DFOB within a biocompatible, slow-release delivery system. 
The dissociation of apoferritin into subunits at pH 2 followed by its reassembly at pH 7.4 
trapped ca. three DFOB inside.79 Investigation showed that these trapped DFOB 
molecules are able to react with Fe3+ to form the corresponding complex. Trapping 
molecules of this kind inside apoferritin provides a useful proof-of-concept for a mode of 
drug delivery. Due to the lack of information (what timescale, how much, where, etc.) 
relevant to the release of DFOB, at this moment it is hard to estimate if this drug delivery 
system can be truly used in therapy.  
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Functional guest species trapped within apoferritin are also finding potential 
applications in cancer therapy. Cancer can be treated by various means including 
chemotherapy and radiation therapy. Doxorubicin is a chemotherapy drug used in the 
treatment of a variety of cancers. In order to enhance potentially its therapeutic index and 
achieve specific delivery to defined cancer cells, doxorubicin was trapped inside 
apoferritin following essentially the same procedure as used for trapping DFOB.41 
Radiation therapy is the use of penetrating beams of radiation to treat disease. However, 
long-term experience of cancer treatment has shown that certain tumor types become 
radioresistant and are very difficult to kill.80 Under this situation, neutron therapy is a 
promising choice, which specializes in treating inoperable, radioresistant tumors 
occurring anywhere in the body.81 Uranium is a promising metal to be used in neutron 
therapy. However, its extensive use is limited by the toxicity of uranium compounds, the 
low uptake by common metal chelators, and the lack of methodology to attach hundreds 
of atoms per antibody. To solve these problems, Hainfeld loaded apoferritin with 800 
uranium atoms, attached Fab’ antibody to the loaded product, and demonstrated the 
retention of immunoreactivity by this complex.82 To achieve the high loading of 
apoferritin required for potential therapy (> 300 uranium atoms per apoferritin), the 
author developed a strategy to actively concentrate uranium within the central cavity of 
apoferritin. This strategy relied on controlling the solubility of the uranyl ion by pH: 
uranyl acetate is soluble at pH ≤ 4.5, but becomes insoluble uranyl complexes at higher 
pH. By soaking apoferritin with uranyl acetate at pH 4 and then raising the pH to ≈ 7, the 
author successfully nucleated and grew uranium crystals inside apoferritin. 
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3.3. Bionanotechnology 
Bionanotechnology is emerging as an interdisciplinary field for chemists, material 
scientists, and biomedical researchers. Biomolecules are attractive nanoreactors for the 
artificial synthesis of homogeneous metal nanoparticles, semiconductor nanoparticles, 
and nanofunctional bioconjugates.83 One typical example is the construction of a two-
dimensional crystal array of PbS nanoparticle-loaded chaperonin protein on the channel 
part of MOS transistors, which worked successfully as charge storage nodes opening 
potential applications in flash memory technology.84 Nanoparticles are fundamental 
elements in nanotechnology. The inner cavity of apoferritin provides an ideal spatially 
restricted chemical reaction chamber for nanoparticle synthesis. 
Mann and co-workers have done pioneering work in applying ferritin to different 
problems in nanotechnology. In their earliest contribution, iron sulfide, manganese oxide, 
uranyl oxyhydroxide were respectively synthesized in apoferritin.85 Research in this field 
has since attracted worldwide attention; examples will be summarized in the next chapter.  
It may be noted that in the synthetic procedure, apoferritin is typically mixed with a 
few thousand equiv of metal ions. It had been generally assumed that all the metal ions 
were sucked into apoferritin during the incubation. Therefore, no dialysis was carried out 
before the mineralization step.86-89 However, in a 2004 paper reporting the photocatalytic 
synthesis of copper particles from Cu2+ by the ferrihydrite core of ferritin, the authors 
found out that the Cu particle dimensions as measured by TEM and DLS were larger than 
the 12-nm ferritin, which suggested that the formation of Cu nanoparticles could either 
occur outside the protein cage, or that the protein cage was disrupted during formation of 
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the Cu particle within the protein.90 Later in 2007 the study of gold nanoparticles 
synthesized in the presence of apoferritin revealed that it is not correct to assume that all 
the metal ions can concentrated inside apoferritin after incubation.91 Two 2010 papers 
figured out the importance of adding a dialysis step in the synthetic procedure. In the gold 
nanoparticle paper, HSAF was mixed with HAuCl4 in the 1-to-1000 molar ratio. Before 
adding NaBH4, the pale-yellow solution was applied to a desalting column to remove free 
HAuCl4.92 The same column and essentially the same procedure were also used for the 
Au-Ag alloy nanoparticle paper.71  
An intriguing field of ferritin research toward bio-nanotechnological applications is the 
fabrication of two-dimensional (2-D) ferritin assemblies. A remarkable work was done by 
Yoshimura et al., who developed a simple method for making 2-D ferritin arrays using a 
new spreading technique.93 In this paper, the addition of 10 mM Cd2+ to the aqueous 
subphase is a critical factor in optimizing the 2-D array formation. In the absence of Cd2+, 
only random adsorption of ferritin molecules to the unfolded protein film was observed. 
Cd2+ should play the same role as explained in Section 2.1 of this chapter. In a later 
publication, Yoshimura and co-workers fabricated iron and indium nanoparticle arrays on 
carbon film and silicon wafer using a protein crystal lattice, which has potential use in a 
wide variety of electronic and semiconductor devices.94 Self-assembly methods, 
combined with protein design and semiconductor organic/inorganic interfaces, are 
expected to herald the future of nanotechnology-based advanced manufacturing.  
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Figure 1.1. Ribbon diagram of the α-carbon backbone of a HSAF subunit. Image was 
generated using PyMol.95  
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Chapter 2: Apoferritin-Stabilized Gold Nanoparticles 
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1. Introduction 
Biomolecule-inorganic nanoparticle assemblies are the subject of growing research, 
and have become important for advances in catalysis, sensing, optoelectronics and 
biomedical applications. Biomolecules such as oligonucleotides,1-8 peptides,9-12 and 
proteins13-17 offer rich structural and functional diversity for synthesizing inorganic 
nanoparticles of different compositions, sizes, and shapes, and controlling their 
arrangement into complex architectures.18,19 The need for more sensitive bioanalytical 
assays have made gold nanoparticles a particular focus of current research.20-29 Gold 
nanoparticles are useful for applications such as colorimetric sensing,30-32 contrast-
enhanced optical imaging,33 and photothermal therapy,34 based on strong absorption from 
the gold surface plasmon resonance (SPR) band, which is sensitive to local 
environment.35-37 For uses of gold nanoparticles in aqueous solutions, it is important to 
enhance physicochemical stability and solubility through passivation of the gold surface. 
We chose HSAF as the passivating agent, because unlike commonly used stabilizers, 
apoferritin is comprised of twenty-four four-helix bundles that self assemble to form a 
12-nm spherical protein with an 8-nm diameter cavity. We show in this work that gold 
nanoparticles form on the outer protein surface, leaving the cavity empty for subsequent 
reactions. The differential reactivity of HSAF interior and exterior surfaces, and the 
ability to store small molecules within the protein cavity,38-40 provide opportunities to 
fabricate multifunctional nanomaterials with controlled molecular features. It is well 
known that HSAF can react with Fe2+ and dioxygen to store as many as 4000 Fe3+ ions as 
a ferrihydrite core within its interior.41 Apoferritin also templates the synthesis of various 
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inorganic particles, including metals, metal oxides, and semiconductors.42 Growth of 
particles inside apoferritin requires addition of metal ions together with a reductant. The 
protein shell is perforated by narrow hydrophilic channels at the threefold symmetry axes 
that are believed to promote the transport of metal ions into the cavity.15,43,44 Previous 
studies have added metal ranging from a few hundred to several thousand ions per HSAF 
holoprotein, as summarized in Table 2.1. Transmission electron microscopy (TEM) data 
indicated that the nanoparticles typically grew inside the apoferritin cavity. Importantly, 
the metal ion sources were divalent cations, with two exceptions being Cr3+ and Au+.45,46 
Although the formation of Au2S nanoparticles inside HSAF was recently described,45,46 
the present study is the first detailed report on the addition and reduction of Au3+ to form 
Au0 nanoparticles outside of HSAF. The main goal in the present manuscript is not to 
prepare efficient biocatalysts but to get a fundamental understanding about the HSAF-
gold system, how HSAF stabilizes gold particles, and how one of the two different 
synthetic routes used gives better surface passivation/better access to reactants so that 
gold can still participate in catalysis. We elucidated the structure and activity of ferritin-
gold nanoparticles formed under various reaction conditions. Methods for characterizing 
these protein-gold assemblies may be applied to other bio-inorganic systems. 
Several groups have sought to develop methods for preparing spherical gold particles 
in a range of diameters,37,47-50 as important physical properties vary with the dimensions 
of the gold.35 The SPR maximum is normally between 520 and 530 nm for spherical gold 
particles less than 20 nm in diameter, but this absorption feature can vary widely, 
depending on the size, aspect ratio, and aggregation state of the particles.19 Whetten and 
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colleagues studied the absorption spectra of a series of nanocrystalline gold particles, and 
found that the SPR band became identifiable only for structures greater than 2.0 nm in 
diameter.35 Researchers have employed capping agents, such as alkanethiols, surfactants, 
peptides, or proteins, in order to confine gold particle growth on the nanoscale and 
passivate the surface.19 One example is the globular protein bovine serum albumin 
(BSA).51-53 The José-Yacamán group reported the synthesis of gold nanoparticles smaller 
than 2 nm through NaBH4 reduction in the presence of BSA. This eliminated the need for 
stabilizing agents, such as citrate, or linker molecules, such as glutaric dialdehyde.51 
Using a different approach, Singh et al. produced gold nanoparticles by in situ reduction 
of gold ions in a foam generated by passing N2 gas through a BSA solution.52 The protein 
played a role as both foaming and stabilizing agent. The photoreduction of gold 
nanoparticles in the presence of BSA has also been described, and it was noted that in 
addition to BSA, several other proteins can stabilize the gold.53 Besides the use of 
proteins, water-soluble, biocompatible gold nanoparticles of different sizes have also 
been synthesized using dendrimers,54 and short peptides such as tiopronin37 and 
glutathione as capping agents,55 as well as a dodecapeptide identified from a phage 
display library.56 
In a broad context, apoferritin serves as a useful paradigm for studying protein-metal 
nanoparticle interactions. We found that upon reduction of several thousand equiv of 
AuCl4- in the presence of HSAF, apoferritin stabilized the gold particles in aqueous 
solution through exterior surface interactions. This is similar to copper-HSAF systems, 
where Cu0 particles larger than the ferritin cavity were stabilized by the protein in 
35 
 
water.57 We report several methods for probing protein-gold assemblies and compare the 
properties of Au-HSAF particles synthesized under different conditions. Key features of 
the gold-apoferritin complexes, such as stability and particle morphology, were affected 
by the nucleation, growth, and final passivation of the particles, which varied with the 
reaction conditions. We begin to consider these factors in this work. 
 
2. Experimental 
2.1. Reagents 
All chemicals were of analytical reagent grade and used without further purification, 
unless otherwise stated. Sigma: horse spleen apoferritin (obtained as a 53 mg/mL, 0.15 M 
NaCl solution); horse spleen ferritin (HSF, obtained as an 85 mg/mL, 0.15 M NaCl 
solution); 3-(N-morpholino)propanesulfonic acid (MOPS). Fisher: hydrogen tetrachloro-
aurate(III) hydrate (HAuCl4·xH2O, p.a.). Acros: gold(III) chloride (AuCl3), and 4-
nitrophenol. Aldrich: sodium borohydride (NaBH4). All solutions were prepared using 
deionized water purified by Ultrapure Water Systems. 
2.2. Sample preparation 
AuCl4- was used as the gold ion source, while NaBH4 or MOPS was used as the 
reducing agent. AuCl3 was also tested as the gold ion source following the same synthetic 
procedure. HSAF (3.79 μL, 0.11 mM) was dissolved in a 2-mL buffer solution (0.4 M 
NaCl, 0.1 M KH2PO4, pH 7.5). 16.66 μL of 0.1 M AuCl4- (4000 equiv per HSAF) was 
added and the mixture was stirred for 1 h at rt. 50 μL of 0.1 M NaBH4 (3 equiv per 
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AuCl4-) or 83.3 μL of 1 M MOPS (50 equiv per AuCl4-) was then added to reduce the 
gold ions and the resulting solution was stirred for 1 h. This solution was centrifuged at 
5000 rpm for 10 min (Eppendorf Centrifuge 5415D). The Au-HSAF product was 
subsequently passed through a gel filtration column (Econo-Pac 10DG column, Bio-Rad; 
eluent: 0.4 M NaCl, 0.1 M KH2PO4, pH 7.5). 
2.3. Physical measurements 
UV-visible (UV-Vis) absorption spectra and kinetics monitoring absorption changes 
were recorded on an Agilent 8453 UV-Vis spectrophotometer with temperature controller 
(25 °C) and magnetic stirrer (300 rpm, Agilent 89090A), using a quartz cuvette with 1-
cm path length. Chemical reactions were monitored at 530 nm to track the SPR band 
associated with gold particle formation. Circular dichroism (CD) measurements were 
obtained on a polarimeter (AVIV, model 62A DS) in the temperature range of 4-96 °C 
with a 1-mm path length optical cell. High-resolution TEM data and images were 
collected using a JEOL 2010F TEM with 0.23 nm point-to-point resolution at the Penn 
Regional Nanotechnology Facility. Low-resolution TEM data and images were collected 
at the Penn Biomedical Imaging Facility. Inductively coupled plasma optical emission 
spectroscopy (ICP-OES) was performed by Galbraith Laboratories, Inc. to determine the 
gold stoichiometry of Au-ferritin samples in solution. The Bio-Rad Protein Assay, based 
on the Bradford method,58 was used to determine the concentration of HSAF. 
2.4. Fast protein liquid chromatography (FPLC) 
HSAF solution (2 mL, 0.208 μM) was stirred with AuCl4
- (41.6 μL, 0.1 M) before 
adding NaBH4 (124.8 μL, 0.1 M). Following reduction for 1 h, the sample was divided 
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into four equal portions and additional HSAF solution was added to three of those 
portions, to achieve a final HSAF concentration of 0.417 μM, 0.833 μM and 1.875 μM. 
The samples were then left at 4 °C overnight, centrifuged at 5000 rpm for 10 min, and 
passed through a Superdex S200 column (Akta FPLC system, GE Healthcare) running 
0.15 M NaCl, 0.02 M Tris, pH 7.4 buffer (TBS) and monitoring absorption at 280 nm. 
In a parallel experiment, HSAF solution (2 mL, 0.208 μM) was stirred with AuCl4- 
(41.6 μL, 0.1 M) before adding MOPS (208 μL, 1 M). Following reduction for 1 h, the 
sample was divided into three equal portions and more HSAF was added to two of these 
portions, to achieve a final HSAF concentration of 0.417 μM and 0.833 μM. The samples 
were then left at 4 °C overnight, centrifuged at 5000 rpm for 10 min, and passed through 
a Superdex S200 column running TBS and monitoring absorption at 280 nm. The 
Superdex S200 column was calibrated by using high molecular weight standards as 
described in the manufacturer’s protocol. 
2.5. Catalytic properties 
The reduction of 4-nitrophenol by NaBH4 in the presence of Au-HSAF catalyst was 
studied in 2-mL solutions, with an identical procedure for NaBH4-reduced and MOPS-
reduced Au-HSAF. In a standard quartz cell with a 1-cm path length, 50 μL of 0.1 M 
NaBH4 was mixed with 0.5 mL of 0.2 mM 4-nitrophenol. 1.25 mL of H2O was then 
added. UV-Vis measurements were initiated with the addition of 0.2 mL of 50 nM Au-
HSAF solution. For experiments measuring the effects of extra HSAF on catalytic 
activity, 3, 10, or 30 μL of 10 μM HSAF were premixed with Au-HSAF solution and 
then added together to the solution mixture of 4-nitrophenol and NaBH4. The kinetics of 
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4-nitrophenol reduction were monitored by UV-Vis spectroscopy, with spectra recorded 
at 15-s intervals in a scanning range of 200-800 nm at 25 °C. 
2.6. Effect of reaction time on catalysis 
NaBH4- or MOPS-reduced Au-HSAF samples were prepared following the synthetic 
procedure specified in Section 2.2., the only difference being that after adding NaBH4 or 
MOPS, the resulting solution was stirred for up to 24 h. The concentrations of the Au-
HSAF samples were adjusted to reach the same absorption intensity at 530 nm (O.D.530nm 
= 0.66). To study the effect of reaction time on catalysis, in a standard quartz cell with a 
1-cm path length, 50 μL of 0.1 M NaBH4 was mixed with 0.5 mL of 0.2 mM 4-
nitrophenol. 1.25 mL of H2O was then added. UV-Vis measurements were initiated with 
the addition of 0.2 mL of the above Au-HSAF solution. The kinetics of 4-nitrophenol 
reduction were monitored by UV-Vis spectroscopy, with spectra recorded at 15-s 
intervals in a scanning range of 200-800 nm at 25 °C. 
 
3. Results and Discussion 
During sample preparation, HSAF was first stirred for 1 h with 4000 equiv AuCl4- at 
25 °C to afford a clear, pale yellow solution. No gold was observed to precipitate during 
this mixing process. The gold ions were then reduced by NaBH4 (3 equiv per AuCl4-) or 
MOPS (50 equiv per AuCl4-) to yield Au0 particles, and the solution became reddish-
purple during a 1 h reaction. Reduction times greater than 1 h led to decreased SPR band 
intensity. Au-HSAF was purified by gel filtration chromatography in ca. 30% (NaBH4-
reduced sample) and 50% (MOPS-reduced sample) overall yields, based on the starting 
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quantity of HSAF, as determined by the Bio-Rad Protein Assay. ICP-OES measurements 
revealed that the average Au atom-to-HSAF 24-mer ratio was 1500:1. 
High-resolution TEM was used to characterize the structure of the Au-HSAF samples. 
The TEM images (Figures 2.1A and 2.1B) and the particle size histograms (Figures 2.1C 
and 2.1D) showed broad particle size distributions with mean diameters of 3.6 ± 1.2 and 
15.4 ± 4.5 nm for NaBH4-reduced and MOPS-reduced Au-HSAF, respectively. Energy 
dispersive spectroscopy (EDS) positively identified gold in the nanoparticle samples 
(Figure 2.1E). Particle atomic spacings were 0.245 nm (Figure 2.1F). The lack of 
correlation between particle morphology (mean diameter and the range of sizes) and the 
8-nm diameter apoferritin interior suggested that particle growth and stabilization did not 
occur within the protein cavity. The average diameter of MOPS-reduced gold particles 
was approximately twice the size of the 8-nm HSAF cavity, whereas the NaBH4-reduced 
gold particles were less than half the diameter of the HSAF cavity. 
Figure 2.2A shows a high-resolution TEM image of NaBH4-reduced Au-HSAF, which 
was stained with 2% phosphotungstic acid (PTA). PTA was largely excluded from the 
HSAF interior, and therefore provided negative contrast for the protein. This TEM image 
provided strong evidence that even the smaller NaBH4-reduced gold nanoparticles (black 
circles) did not form inside the cavity and were forced to reside at the outer HSAF 
surface (larger white circles). Similar results were obtained from low-resolution TEM 
images of MOPS-reduced Au-HSAF (Figure 2.2B). 
We postulate that the gold is binding with highest probability to amino acids with 
sulfur-, nitrogen-, and oxygen-containing side chains at pH 7.5, all of which are 
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positioned prominently on the outer surface of HSAF. These residues are expected to 
bind gold ions, where gold is subsequently reduced and gold particles nucleated on the 
outer protein shell. The anionic protein channels of ferritin promote the transport of 
divalent cations into the cavity (Table 2.1), but are not well suited to transport larger gold 
complexes that are neutral (AuCl3) or monoanionic (AuCl4-). Thus, in a competition 
between Au3+ binding and reduction at the outer ferritin surface and metal ion transport to 
the protein interior, it appears that most of the gold is reduced at residues on the protein 
exterior. Mutagenesis experiments are ongoing in our lab to probe gold-ferritin 
interactions more directly. 
In addition to electrostatic considerations, we hypothesized that the different gold 
particle size distributions should relate to differences in the kinetics of gold particle 
formation. NaBH4 is a strong reducing agent that rapidly reduced AuCl4- and likely 
nucleated numerous particles, thereby depleting the gold salt before larger particles were 
able to form. MOPS is a much milder reducing agent, yielding slower gold particle 
nucleation and growth that was strongly mediated by the protein. 
Figure 2.3A shows the kinetics of AuCl4- reduction by NaBH4 in the presence and 
absence of HSAF, monitored at 530 nm. In both samples, the SPR band reached a 
maximum in five seconds, indicating kinetics at least as fast as the mixing time of our 
apparatus. In the absence of HSAF, the absorption was observed to decrease from its 
initial maximum due to the precipitation of gold colloid. However, the SPR band 
observed in the presence of HSAF remained unchanged, indicating that the gold 
nanoparticles were stabilized by the protein in solution. As a second control experiment, 
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AuCl4- was stirred with HSAF without the addition of the reducing agent NaBH4 (Figure 
2.3A) or MOPS (Figure 2.3B). AuCl4- was not reduced on the same timescale of seconds-
to-minutes, as evidenced by the lack of an SPR band. In fact, with only HSAF as the 
reductant, the formation of gold nanoparticles required weeks of stirring in the dark. In 
parallel with these studies, we attempted to form gold nanoparticle-protein assemblies via 
a stepwise process of first reducing Au3+ (16.66 μL, 0.1 M) in solution with NaBH4 (50 
μL, 0.1 M) or MOPS (83.3 μL, 1 M) for 1 hour and then adding HSAF (3.79 μL, 0.11 
mM). The solution mixture was stirred for 1 hour. Bulk gold precipitation was 
unambiguously observed, and the sequential addition of HSAF failed to produce soluble 
gold nanoparticles under these conditions. 
Figure 2.3B shows the kinetics of AuCl4- reduction by MOPS in the presence and 
absence of HSAF, which occurred on the timescale of minutes. Interestingly, AuCl4- 
reduction was measurably faster in the absence of HSAF, but the absorption signal 
quickly decreased in this case, indicating the formation and precipitation of insoluble 
gold colloids. Reduction of AuCl4- in the presence of HSAF produced a stable SPR band 
in aqueous solution, again indicating the stabilizing role of the protein. When stored at 4 
°C in buffered solution, Au-HSAF samples remained stable for several months. 
It is noteworthy that the formation of gold nanoparticles via the reaction between 
AuCl4- and MOPS in the absence of other stabilizing agents has been recently 
reported.59,60 The reduction of Au3+ by Good’s buffers such as MOPS was shown to 
occur in 1-electron steps, Au(III)  Au(II)  Au(I)  Au(0), with the buffer serving as 
a mild reducing agent. Electrochemical experiments identified a single anodic peak for 
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MOPS ~ +800 mV vs. Ag/AgCl electrode. The production of soluble gold nanoparticles 
in these reports instead of bulk gold relates to differences in their synthetic procedures, 
including: (i) lower concentrations of reagents in solution, (ii) lack of stirring, and (iii) 
lack of concentrated phosphate salt buffer. In the present study, MOPS is expected to 
reduce Au3+ by similar 1-electron transfer steps. However, the bound protein may affect 
the redox potential of the gold and in some cases block inner-sphere electron transfer 
from MOPS to the gold ions, thereby slowing gold nanoparticle formation. It is of 
considerable benefit that HSAF solubilizes the gold particles formed by MOPS over a 
much wider range of pH than is possible with just buffer in solution.59,60 
Figure 2.4A shows the absorption spectra of Au-HSAF samples reduced by NaBH4 or 
MOPS, which were characterized by the gold SPR band.19,61 The SPR band of MOPS-
reduced Au-HSAF (λmax = 535 nm) showed a 5-nm red shift compared to NaBH4-reduced 
Au-HSAF, with absorption centered at 530 nm. The effect of reducing conditions on the 
SPR maximum may reflect small differences in particle morphology35,62 and aggregation 
state.8 Light scattering was observed for all NaBH4-reduced gold samples, as evidenced 
by an elevated baseline in the UV-Vis spectra (Figure 2.4). To probe the effects of 
possible aggregation, we centrifuged the MOPS-reduced gold particles more rigorously, 
at 13,000 rpm for 10 min. Figure 2.5A shows the absorption spectra of MOPS-reduced 
Au-HSAF products centrifuged at 5000 rpm (solid line) and 13,000 rpm (dashed line). A 
9-nm blue shift of the SPR maxima from 535 nm to 526 nm was observed when the 
sample was centrifuged at the higher rate. The blue shift appeared to be caused entirely 
by a loss of aggregation, not the isolation of smaller gold particles. A representative TEM 
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image and histogram of the particle sizes of MOPS-reduced Au-HSAF centrifuged at 
13,000 rpm are shown in Figures 2.5B and 2.5C, which showed virtually identical 
particle size distributions for samples centrifuged at 5000 and 13,000 rpm. These data 
indicated that for these Au-HSAF particles, the positions of the SPR bands were more 
sensitive to particle aggregation state than size. 
To test whether the exterior surface of ferritin was sufficient for forming stable gold 
particles in solution, AuCl4- was reduced with MOPS under the same conditions using 
HSF instead of HSAF. We hypothesized that the presence of the HSF iron hydroxide 
mineral core should have little effect on gold nanoparticle formation. Consistent with this 
hypothesis, an SPR band of Au-HSF centered at 535 nm was recorded for the MOPS-
reduced sample, which agreed with Au-HSAF. However, for reasons that are still under 
investigation, HSF proved to be worse at stabilizing gold nanoparticles in aqueous 
solution. 
Exploring the gold-protein interactions further, we tested whether the negatively 
charged threefold symmetric channels of HSAF were important for gold nanoparticle 
formation using neutral AuCl3 as the Au3+ source. Figure 2.4B shows the absorption 
spectra of Au-HSAF samples reduced by NaBH4 or MOPS, which gave essentially the 
same results for AuCl3 and AuCl4-. This indicated that the gold ion source, whether 
neutral or negatively charged, had little influence on particle formation. These results, 
together with the TEM data and HSF experiments, supported a model in which gold 
particles were nucleated on the exterior protein surface. 
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We also varied gold ion concentrations at three pH values and monitored the intensity 
of the SPR band, in order to probe a range of conditions for gold nanoparticle formation. 
At a pH of 6.5, 7.5, and 8.5, we added 1000, 4000, or 7000 equiv AuCl4- per HSAF and 
monitored the SPR band upon reduction with either NaBH4 or MOPS. A pH of 7.5 was 
chosen for subsequent experiments because it represented the most biologically relevant 
conditions while retaining the ability to synthesize Au0 nanoparticles in an efficient 
manner. For both reducing agents, it was found that the SPR intensities were enhanced by 
increasing from 1000 to 4000 equiv AuCl4-. For 7000 equiv AuCl4-, the SPR intensities 
decreased in general, more for NaBH4 than when MOPS was the reducing agent. 
Therefore, 4000 equiv AuCl4- per HSAF was chosen for synthetic experiments in this 
work. 
To determine if the gold surface was completely passivated by the protein after 
reduction, samples of Au-HSAF were prepared with excess gold (10,000 equiv) and 
purified by FPLC. The pure Au-HSAF sample was subsequently incubated with 
additional HSAF, and the resulting samples were repurified by size-exclusion 
chromatography. The elution profiles of NaBH4-reduced and MOPS-reduced Au-HSAF 
samples are shown in Figure 2.6. In both cases, FPLC traces monitoring absorbance at 
280 nm showed elution peaks at 7.8 mL and 10.6 mL. The solution eluting at 7.8 mL was 
red but did not precipitate, indicating the presence of gold nanoparticles stabilized by 
associated HSAF. The peak at 10.6 mL did not show any absorbance at 530 nm and was 
found by column calibration to correspond to the molecular weight of pure HSAF (~ 480 
kD).41 The majority of the initial NaBH4-reduced Au-HSAF sample precipitated in the 
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column, as evidenced by the small absorption peaks of the eluted material (Figure 2.6A), 
as well as the red residue that remained on the column. However, addition of extra HSAF 
to these NaBH4-reduced samples greatly increased their stability on the column. The 
absorption peaks in the case of the MOPS-reduced Au-HSAF were much larger, but were 
not greatly enhanced by post-reduction addition of HSAF (Figure 2.6B). Therefore, we 
determined that HSAF, with perhaps some contribution from MOPS, was able to 
passivate the gold surface under slow reduction conditions. Under conditions of rapid 
NaBH4 reduction, HSAF capped the gold nanoparticles much less effectively. 
The thermal stability of Au-HSAF was investigated by circular dichroism 
measurements in which the temperature was increased from 4 to 96 °C at a rate of 0.5 °C 
min-1. Figure 2.7 shows the first differential of the ellipticity signal monitoring α-helical 
content of HSAF at 222 nm. Denaturation or precipitation of the protein at higher 
temperatures caused a reduction in signal. The melting temperature (Tm) was determined 
from the midpoint of the melting curve, where the first derivative was the maximum. 
With melting temperatures of 56 °C (NaBH4-reduced) and 62 °C (MOPS-reduced), Au-
HSAF had lower thermal stability than HSAF, Tm = 71 °C. 
We also examined the stability of Au-HSAF over a wide range of pH values. Figure 
2.8 shows the pH stability of HSAF and Au-HSAF reduced by NaBH4 or MOPS. 
Buffered solutions at pH 7.5 were titrated with 1 M HCl and NaOH to achieve pH 2-12, 
and centrifuged at 5000 rpm for 10 min to remove any precipitate before spectral 
characterization. The stability of the Au-HSAF sample as a function of pH was 
determined by measuring the change of the absorption intensity at 530 nm, while in a 
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control experiment HSAF alone in solution was monitored at 280 nm. The absorbance 
intensities of all three samples remained generally unchanged at pH values above 7, 
which indicated comparable stability in alkaline solutions. HSAF effectively stabilized 
the gold particles in aqueous solution from pH 6-12. 
When the pH of the solution was gradually lowered from 7 to 2 in increments of 1 pH 
unit, the absorbance (at 280 nm) decreased for HSAF and even more significantly (at 530 
nm) for both Au-HSAF samples. At pH 2, neither Au-HSAF sample showed an SPR 
band, indicating the absence of soluble gold nanoparticles, whereas they both showed 
protein absorption at 280 nm. Calculations based on the UV-Vis spectra revealed that 
when lowering the pH from 7 to 2, most of the protein remained in solution for HSAF, 
NaBH4-reduced Au-HSAF, and MOPS-reduced Au-HSAF samples. Protonation of the 
exterior protein ligands at low pH should help to dissociate gold from HSAF and yield 
selective gold precipitation. It is also worth noting that by pH 2, the HSAF 24-mer has 
dissociated almost completely into its constituent 4-helix bundles,63 which are likely to be 
less effective at stabilizing gold particles in solution. 
As an indirect method for elucidating the protein-metal nanoparticle interactions, we 
examined the Au-HSAF-catalyzed reduction of 4-nitrophenol by NaBH4. We first tested 
the catalytic properties of NaBH4-reduced Au-HSAF by adding this sample to an aqueous 
solution containing 4-nitrophenol and NaBH4. The rapid conversion of the 4-nitrophenol 
to 4-aminophenol was monitored at 400 nm (Figure 2.9). To exclude the possibility that 
this reduction might be activated by the protein alone, HSAF was added to 4-nitrophenol 
and NaBH4 as a control. No change in the phenol absorbance was observed, as shown in 
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Figure 2.10. In the absence of the Au-HSAF catalyst, the absorbance at 400 nm also 
remained unaltered, indicating that NaBH4 was unable to reduce 4-nitrophenol directly. 
These results proved that NaBH4-reduced Au-HSAF catalyzed the reduction of 4-
nitrophenol by NaBH4. This reaction has been attributed to a gold particle-mediated 
electron transfer from BH4- to 4-nitrophenol.64,65 
Figure 2.10 shows the plot of 400-nm absorption versus time for the Au-HSAF-
catalyzed reduction of 4-nitrophenol by NaBH4 in the presence of different 
concentrations of additional HSAF. Because the concentration of NaBH4 added to this 
system was very high relative to 4-nitrophenol, it was reasonable to assume that the 
concentration of NaBH4 remained constant during the reaction. Data for ln(A400) were 
plotted versus time and linear fitting gave a reaction rate constant, k = 1.66 × 10-2 s-1. 
With added HSAF (15, 50, and 150 nM), the reaction was slowed (k = 1.23 × 10-2, 1.04 × 
10-2, and 0.97 × 10-2 s-1), which suggested that the extra protein blocked the access of the 
substrate to the gold particles, either by increasing the surface coverage or the 
aggregation state of the particles. This indicated an association process between free 
HSAF and Au-HSAF in the NaBH4-reduced gold samples, which was consistent with the 
results of the FPLC study using the same samples. 
The catalytic effects of the MOPS-reduced Au-HSAF sample were also examined. 
Figure 2.10 shows a plot of 400-nm absorbance intensity versus time for the Au-HSAF-
catalyzed reduction of 4-nitrophenol by NaBH4. In contrast to the previous study, 
substrate reduction was extremely slow, and adding more HSAF had no noticeable effect 
on the reaction. The catalyst was presumed to be less accessible to 4-nitrophenol, based 
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on greater coverage of the gold surface with protein, likely in combination with greater 
particle aggregation. Another contributing factor may have been the lower total surface 
area of the larger MOPS-reduced gold particles, which numbered fewer in solution. The 
catalysis results corroborated data from UV-Vis spectroscopy, reduction kinetics, FPLC, 
thermal and pH stability studies, and provided strong evidence for MOPS-reduced Au-
HSAF samples being much better passivated at neutral pH than NaBH4-reduced Au-
HSAF. 
As an indirect measure for whether the Au-HSAF reaction went to completion in the 1 
h standard synthetic protocol, the gold-HSAF reaction solution was stirred for between 1 
and 24 h after adding either NaBH4 or MOPS. Figure 2.11 shows the plots of 400-nm 
absorption versus time for the reduction of 4-nitrophenol by NaBH4 using NaBH4-
reduced Au-HSAF particles that were reacted for 1, 6, 12, or 24 h. Nanoparticles formed 
in the longer reactions gave virtually identical kinetics for the catalytic reduction of 4-
nitrophenol. Au-HSAF prepared by reduction with MOPS for up to 24 h exhibited 
similarly little catalytic activity (Figure 2.11). This indicated that Au-HSAF particle 
formation was indeed complete on the 1-hour time scale, under both sets of reducing 
conditions. Data from the previous FPLC experiments showed that for NaBH4-reduced 
samples, the gold surface remained unpassivated and reactive to additional HSAF. Thus, 
the catalysis results helped to confirm that the difference in catalytic activity between 
NaBH4- and MOPS-reduced Au-HSAF was due to intrinsic differences in surface 
passivation between the two samples, and all of the HSAF in solution was reacted within 
1 h during gold reduction and particle formation. 
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4. Conclusions 
In summary, we report a practical method for synthesizing spherical gold nanoparticles 
using horse spleen apoferritin as the stabilizing agent. Au3+ reduction occurred much 
more rapidly with NaBH4 than MOPS. Gold nanoparticles were shown by TEM to reside 
on the protein outer surface. A 5-nm red-shifted absorbance of MOPS-reduced gold 
particles was based mostly on their aggregation in solution; more passivated and less 
aggregated particles could be obtained through additional centrifugation. Several studies 
indicated that NaBH4-reduced Au-HSAF was generally less stable than MOPS-reduced 
samples. This was probably due to rapid reduction by NaBH4, which resulted in fewer 
stabilizing interactions between the gold and protein. Incomplete gold surface coverage 
explained why NaBH4-reduced Au-HSAF effectively catalyzed the reduction of 4-
nitrophenol by NaBH4. The conjugation of ferritin proteins to metal nanoparticles 
provides new routes to further particle functionalization and assembly by labeling surface 
amino acids.66,67 The techniques employed in this work for studying ferritin-gold 
nanoparticle assemblies may be readily applied to other protein-metal colloid systems. 
 
5. Future Directions 
This chapter reports the stabilization of gold nanoparticles by HSAF. In this work, 
AuCl4- was mixed with HSAF, and then the reducing agent (NaBH4 or MOPS) was 
added. There was no dialysis before adding the reducing agents. And reduction was 
performed in only one step, instead of achieving nucleation, followed by particle growth. 
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TEM showed that gold nanoparticles resided on the protein outer surface. This result 
indicated that the majority part of AuCl4- was not loaded into HSAF during the mixing 
step. 
Inspired by two recent publications,68,69 I performed the dialysis before adding the 
reducing agent ascorbic acid. In the experiment, HSAF (100 μM, 1 μL) was mixed with 
AuCl4- (10 mM, 133 μL) in 0.5-mL phosphate buffer. After dialyzing overnight, ascorbic 
acid (0.1 M, 40 μL) was added. TEM images of these samples were measured (Figure 
2.12), which revealed that gold nanoparticles of a diameter smaller than the cavity of 
HSAF were synthesized. We expect that this synthetic method is applicable to other 
ferritin proteins, such as human ferritin and thermophilic ferritin. 
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Table 2.1. Literature survey of inorganic complexes formed with HSAF. 
________________________________________________________________________ 
Material  Metal ion source Metal:HSAF ratioa Reference 
________________________________________________________________________ 
metals 
Pd   PdCl42-   500   70 
Cu   Cu2+   225   71 
Co   Co2+   not specified  72 
Ni   Ni2+   not specified  72 
  
metal oxides, hydroxides, and oxyhydroxides 
FeOOH  Fe2+   4500   73 
Fe3O4   Fe2+   3000   74 
U oxide  UO22+   4000   75 
U oxo complex UO22+   800   76 
MnOOH  Mn2+   3000   77 
MnOOH  Mn2+   1200   78 
CoOOH  Co2+   2250   79 
CoOOH  Co2+   1500   78 
Cr hydroxide  Cr3+   4800   45 
Ni hydroxide  Ni2+   8000   45 
 
semiconductors 
CdS   Cd2+   55 ~ 275  80 
CdSe   Cd2+   1000   81 
ZnSe   Zn2+   1500   82 
Au2S   Au+   3000   46 
________________________________________________________________________ 
a: Number indicates initially added metal ions per HSAF 24-mer protein. 
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Figure 2.1. (A) TEM image of Au-HSAF reduced by NaBH4. (B) TEM image of Au-
HSAF reduced by MOPS. (C) Histogram of the particle sizes of the sample in (A), 222 
particles analyzed. (D) Histogram of the particle sizes of the sample in (B), 110 particles 
analyzed. (E) Energy dispersive spectrum of representative Au-HSAF sample placed on 
copper specimen grid. (F) The atomic gold lattice spacings of an Au-HSAF sample. 
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Figure 2.2. TEM images showing gold nanoparticles (dark black circles) associated with 
the exterior surface of HSAF (white rings, examples outlined in red). AuCl4- was reduced 
by (A) NaBH4 or (B) MOPS, resulting in gold particles with different size distributions. 
(A) was imaged at 200 kV using phosphotungstic acid (PTA) stain to create negative 
contrast for protein. (B) was imaged at 120 kV using an uranyl acetate stain; the larger 
white circles are an artifact caused by the stain drying process. 
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Figure 2.3. (A) Kinetics traces of AuCl4- reduction by NaBH4 in the presence () or 
absence () of HSAF. Kinetics trace of AuCl4- stirred with HSAF without adding 
NaBH4 (); no particle formation was observed to occur on this timescale. (B) Kinetics 
traces of AuCl4- reduction by MOPS in the presence () or absence () of HSAF. 
Kinetics trace of AuCl4- stirred with HSAF without MOPS (). Reactions were 
monitored at 530 nm. 
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Figure 2.4. (A) Absorption spectra of Au-HSAF reduced by NaBH4 (solid line) or MOPS 
(dashed line) using AuCl4- as the gold ion source. (B) Absorption spectra of Au-HSAF 
reduced by NaBH4 (solid line) or MOPS (dashed line) using AuCl3 as the gold ion 
source. 
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Figure 2.5. (A) Absorption spectra of MOPS-reduced Au-HSAF products centrifuged at 
5000 rpm (solid line) and 13,000 rpm (dashed line), respectively. (B) TEM image of 
MOPS-reduced Au-HSAF centrifuged at 13,000 rpm. (C) Histogram of the particle size 
of the sample in (B) (192 particles analyzed). 
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Figure 2.6. (A) FPLC elution profiles of NaBH4-reduced Au-HSAF (0.208 μM) with 0 
μM HSAF (solid line), 0.417 μM HSAF (dashed line), 0.833 μM HSAF (dotted line) and 
1.875 μM HSAF (dashed dotted line). (B) FPLC elution profiles of 0.208 μM MOPS-
reduced Au-HSAF with 0 μM HSAF (solid line), 0.417 μM HSAF (dashed line) and 
0.833 μM HSAF (dotted line). The traces were scaled such that the area of the gold-
protein peak (at 7.8 mL) was proportional to the initial UV-Vis absorbance measurement 
recorded at 530 nm. FPLC traces were monitored at 280 nm, where both the gold and 
protein absorb. 
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Figure 2.7. Thermal stability studies of HSAF (solid line), Au-HSAF reduced by NaBH4 
(dashed line) and MOPS (dotted line). The curves were normalized to the same intensity. 
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Figure 2.8. pH stability of HSAF () and Au-HSAF reduced by NaBH4 () and MOPS 
(). For HSAF, the normalized absorbance intensities were monitored at 280 nm; for 
Au-HSAF, the normalized absorbance intensities were monitored at 530 nm. All three 
curves were normalized to the highest band intensities of each sample to facilitate 
comparisons of pH stability. 
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Figure 2.9. UV-Vis absorption spectra for the reduction of 4-nitrophenol (50 μM) by 
NaBH4 (2.5 mM) in the presence of NaBH4-reduced Au-HSAF (5 nM protein) as catalyst. 
Solid line, initial spectrum; dashed line, final spectrum.  
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Figure 2.10. Plots of 400-nm absorption versus time for the reduction of 4-nitrophenol 
(50 μM) by NaBH4 (2.5 mM) using NaBH4-reduced Au-HSAF (5 nM protein) as catalyst 
in the absence () and presence of different concentrations of additional HSAF: 15 nM 
(); 50 nM (); 150 nM (); and, using MOPS-reduced Au-HSAF (5 nM protein) as 
catalyst (). Reaction of 4-nitrophenol and NaBH4 in the presence of HSAF alone (5 nM 
protein, no gold) was included as a control (). Values in parentheses represent the final 
reaction concentrations.  
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Figure 2.11. Plots of 400-nm absorption versus time for the reduction of 4-nitrophenol 
(50 μM) by NaBH4 (2.5 mM) using NaBH4-reduced Au-HSAF, which was synthesized 
with different reduction times: 1 h (); 6 h (); 12 h (); 24 h (); and using MOPS-
reduced Au-HSAF (), which was synthesized with 24-h reduction time. 
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Figure 2.12. Two representative TEM images of HSAF-encapsulated gold nanoparticles 
reduced by ascorbic acid. 
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Chapter 3: Binding of Gd-Chelates to Ferritin 
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submitted. 
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1. Introduction 
Several transition metal complexes have been found to serve useful roles as medical 
therapeutic and diagnostic agents.1-5 Nevertheless, the rational design of inorganic drugs 
remains an elusive challenge. The ligands bound to the metal ion (i.e., the primary 
coordination sphere) can tune the kinetic and thermodynamic stability of the complex, as 
well as reactions with specific protein or nucleic acid targets. Evidence is growing that 
many metallodrugs also interact with common human serum proteins in vivo.6-9 This 
interaction alters drug bioavailability in unpredictable ways, and may produce unwanted 
drug side effects.10 Such interactions particularly impact the design of metallo-diagnostic 
agents, where high clearance rates (via the kidney or liver) are typically desirable. Prime 
examples are gadolinium chelates used for magnetic resonance imaging (MRI), which are 
delivered i.v. to patients. Roughly half of the ~30 million MRI procedures performed in 
the U.S. annually involve contrast-enhancing agents, e.g., Gd(DTPA)2- (gadopentetate 
dimeglumine) or Gd(DTPA-BMA) (gadodiamide) (Figure 3.1). Since the development of 
Gd(DTPA)2- and Gd(DTPA-BMA) more than 20 years ago, most reports have suggested 
that these drugs are inert in vivo.11 However, Caravan et al. recently provided conclusive 
evidence of weak binding to many different serum proteins, including human serum 
albumin (HSA) and lysozyme.12 Here, we investigate whether these commonly employed 
Gd-chelates also bind the serum enzyme apoferritin and can affect its iron mineralization 
activity. 
Renewed interest in the biological interactions of Gd-chelates has arisen from a 
cutaneous, sclerodoma-like disease named nephrogenic systemic fibrosis (NSF), first 
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recognized in 2000.13 Figure 3.2 shows the sclerotic plaque with calcinosis on the back 
arm of the patient as an example of NSF.14 NSF has been observed in a small percentage 
of patients with severe or end-stage renal failure who were administered Gd-chelates, 
including Gd(DTPA)2- and Gd(DTPA-BMA).15 Skin biopsies from NSF patients indicate 
high concentrations of Gd in the diseased tissue.16 A hazard for patients who suffer from 
renal insufficiency is that Gd-chelates circulate in the body for an extended time (34 ± 23 
h), compared to 1.3 ± 0.3 h elimination half-life in healthy volunteers.17 Long circulation 
times are likely to promote serum protein interactions. A retrospective study18 of ten 
patients administered gadodiamide found an increase of serum iron from 650 to 990 
ng/mL and an increase of serum ferritin from 428 to 1640 ng/mL (data are median 
values). This suggested to us a possible interaction between Gd-chelates and ferritin, 
which to our knowledge has not been investigated previously. 
For this first study, we examined the interaction of Gd(DTPA)2- and Gd(DTPA-BMA) 
with HSAF and three recombinant apoferritins: human H-chain (HuHF), human L-chain 
(HuLF), and frog H-chain apoferritin with a proline substitution for conserved leucine 
134 (FHF-L134P). Possessing similar 9-coordinate water-bound structures, Gd(DTPA-
BMA) is non-ionic whereas Gd(DTPA)2- has a -2 charge.19,20 HSAF served as the 
prototypal apoferritin in this study, due to its commercial availability and natural 
combination of H- and L-chain subunits (in a ~1:5 ratio). In humans, both H- and L-chain 
ferritin subunits are present in serum, and these interact non-covalently in different 
stoichiometries to form intact 24-mer assemblies.21 
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2. Experimental 
2.1. Reagents 
In our experiments, all starting materials were purchased and used without further 
purification, unless otherwise specified. Acros: GdCl3; TbCl3·6H2O. Sigma: HSAF. 
Sigma-Aldrich: (NH4)2Fe(SO4)2·6H2O. Fe2+ solutions were freshly prepared from 
(NH4)2Fe(SO4)2·6H2O. Tb3+ solutions were prepared by dissolution of TbCl3·6H2O in 1 
mM HCl. Unreacted Tb3+ was separated from the apoferritin-Tb3+ samples by filtration 
on Centricon® Centrifugal Filter Units. Unless otherwise specified, all experiments were 
performed in the same buffer solution: 50 mM Tris, 50 mM NaCl, pH = 7.0. 
2.2. Gd-chelates 
Gd-chelates were synthesized by the reaction of GdCl3 and corresponding ligands 
following literature precedent.22,23 50 mM stock solutions of Gd(DTPA)2- and Gd(DTPA-
BMA) were prepared by dissolving these solid powders in aqueous solution. Gd(DTPA)2-
: ESI-MS m/z: calcd for M + Na+ C14H18N3O10GdNa, 568.6; found, 568.8. Gd(DTPA-
BMA): ESI-MS m/z: calcd for M + Na+ C16H26N5O8GdNa, 596.7; found, 597.0. Stock 
solutions of Gd(DTPA)2- and Gd(DTPA-BMA) were sent to Galbraith Laboratories, Inc. 
for elemental analysis. The concentrations of elemental Gd, C, and N were analyzed by 
ICP-OES (for Gd) and combustion (for C and N). Gd(DTPA)2-: Anal. Calcd: Gd : C : N = 
1 : 14 : 3. Found: Gd : C : N = 1.00 : 14.81 : 3.06. Gd(DTPA-BMA): Anal. Calcd: Gd : C 
: N = 1 : 16 : 5. Found: Gd : C : N = 1.00 : 16.21 : 4.91. 
2.3. Recombinant proteins 
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HuHF and HuLF cDNA was obtained from Paolo Arosio, and these ferritins were 
expressed and purified following published protocols.24,25 The FHF-L134P cDNA was 
provided by Elizabeth Theil, and the protein was expressed and purified following 
published protocols.26,27 BL21(DE3) pLysS cells containing FHF-L134P plasmid were 
cultured with betaine and sorbitol to maximize correct folding of the expressed FHF-
L134P subunits. Differences in the protocols for synthesizing HuHF, HuLF, and FHF-
L134P are summarized in Table 3.1. HSAF and the three recombinant proteins were 
purified by eluting through a Superdex 200 10/300 GL column (Akta FPLC system, GE 
Healthcare) and collecting fractions at the center of the main peak that correspond to the 
correctly assembled 24-mer. This procedure was performed 3-4 times for each protein in 
order to remove all other proteins and DNA. Protein purity of > 95 % was confirmed by 
gel electrophoresis. HuHF: MALDI-MS m/z: calcd, 21,094.45; found, 21,382.10. HuLF: 
MALDI-MS m/z: calcd, 19,888.48; found, 19,880.64. FHF-L134P: MALDI-MS m/z: 
calcd, 20,460.96; found, 20,537.11. 
2.4. Instrumentation 
Far-UV circular dichroism measurements were performed on an Aviv Model 410 
Circular Dichroism Spectrometer at 25 °C. Experimental conditions: scan rate: 12 
nm/min; data interval: 1.0 nm; protein concentration: 0.2 mg/mL. Tryptophan 
fluorescence was measured at 25 °C with a Varian Cary Eclipse spectrophotometer 
operated with the Cary Eclipse Bio software package. Experimental conditions: 
excitation wavelength: 295 nm; scan rate: 30 nm/min; data interval: 0.5 nm; protein 
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concentration: 0.2 mg/mL. T1 relaxation times were determined using a Bruker mq60 MR 
relaxometer operating at 1.41 T (60 MHz) and at 40 °C. 
MRI studies were performed on a 40 cm bore, 4.7 T horizontal bore magnet (Varian, 
Palo Alto, CA) equipped with a 12 cm I.D. gradient insert with a maximum gradient 
strength of 25 G/cm (Magnex Scientific, Abingdon, UK). For this experiment, 0.5 mL of 
each sample was added into a 3-well plate. Following generation of scout images, 
inversion recovery images were generated using the TOMROP (T One by Multiple Read 
Out Pulses) pulse sequence.28 The TOMROP protocol is an imaging implementation of 
the Look-Locker29 experiment in which the magnetization recovery is sampled many 
times (NTI) using low flip angle read pulses at evenly spaced intervals (TI) following 
inversion. The following imaging parameters were used: slices: 1; slice thickness: 1.0 
mm; FOV: 3×3 cm; averages: 1; flip angle: 10°; TE: 4 ms; TI: n*50 ms; n: 1~120; 
recovery delay: 8 s. The TOMROP data were fitted using a non-linear least squares 
analysis implemented in the Interactive Data Language (Research Systems Inc., Boulder, 
CO) programming environment as described.30 T1 map using the fitted parameters was 
then saved. 
 
3. Results and Discussion 
Procedures for synthesizing Gd-chelates and isolating recombinant proteins are given 
in the experimental section. Gd-chelates were characterized by elemental analysis and 
high-resolution mass spectrometry; apoferritins were purified by FPLC and their identity 
confirmed by MALDI mass spectrometry. Figure 3.3 shows the FPLC elution traces of 
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HuHF, HuLF, and FHF-L134P monitoring absorbance at 280 nm. HSAF (50 μM, 100 
μL) was incubated overnight at 25 °C with varied concentrations of Gd-chelates (1:1 to 
20:1 Gd-to-HSAF subunit ratios). Recombinant HuHF, HuLF, or FHF-L134P was 
incubated with Gd-chelates in a single Gd-to-apoferritin subunit ratio of 5:1. Samples 
were dialyzed to remove unbound Gd-chelates (Figure 3.4). Far-UV circular dichroism 
(Figure 3.5) and tryptophan fluorescence (Figure 3.6) measurements confirmed that 
apoferritin samples exposed to Gd chelates in this way maintained wild-type α-helical 
structure as well as native subunit assembly. To determine the stoichiometry of Gd-
chelate binding to apoferritin, dialyzed samples were digested in a 1:1 volume of 
concentrated HNO3 at 80 °C for 1 h, followed by analysis with inductively coupled 
plasma optical emission spectroscopy (ICP-OES) to determine Gd concentrations. 
Apoferritin concentrations were determined by UV-Vis spectroscopy using the Bradford 
assay and bovine serum albumin as a standard.31 
Figure 3.7 shows the stoichiometry of binding between Gd-chelates and HSAF after 
24-h dialysis to remove any weakly associated Gd. The HSAF-Gd-chelate samples were 
stable in solution, with precipitation occurring only when Gd-to-HSAF subunit ratios 
exceeded 20 to 1. Binding interactions were identified and quantified in dialyzed HSAF-
Gd(DTPA-BMA) solutions, for all Gd(DTPA-BMA)/HSAF ratios. The Gd-to-HSAF 
subunit binding ratio increased in a linear fashion from 0.15 to 1.18 as the Gd-to-HSAF 
subunit mixing ratio increased from 1 to 20. Lack of binding saturation over this 
concentration range indicated one or more low-affinity sites on HSAF for Gd(DTPA-
BMA). Similar non-saturation behavior was observed previously for Cr(TREN) binding 
82 
 
to three frog apoferritins (wt H-chain, wt L-chain, mutant L-chain).4 With addition of 5 
equiv Gd(DTPA-BMA), the stoichiometries of Gd binding to HSAF, HuHF, HuLF, and 
FHF-L134P were 0.33, 0.37, 0.22, and 0.68 per apoferritin subunit, respectively. The 
greater binding capacity of FHF-L134P for Gd(DTPA-BMA) has also been seen 
previously for Cr(TREN), and can be attributed to the greater conformational flexibility 
and higher accessibility of the FHF mutant.4 The fact that significantly more binding was 
observed for FHF-L134P and HuHF suggests that Gd can interact with the di-iron 
ferroxidase sites found in ferritin H subunits. These metal coordination sites are lacking 
in HuLF, while found partially in HSAF (~4 per 24-mer), and exclusively in HuHF and 
FHF-L134P. 
In contrast to the apoferritin-Gd(DTPA-BMA) samples, the dialyzed apoferritin-
Gd(DTPA)2- solutions yielded no bound Gd, as analyzed by ICP-OES. This indicated 
either a lack of association of Gd(DTPA)2- with apoferritin or that any bound 
Gd(DTPA)2- dissociated from apoferritin during the 24-h dialysis procedure. The lack of 
binding between Gd(DTPA)2- and apoferritin is likely a result of electrostatic forces: the 
Chasteen lab showed that positively charged organic radicals penetrate into apoferritin 
much more efficiently than do negatively charged radicals.32 It is established that cations 
such as hydrated Fe2+ gain access to the ferritin interior via threefold pores lined with 
negatively charged residues. 
To investigate whether more transient interactions occur between Gd(DTPA)2- and 
HSAF, we performed relaxivity-based binding measurements. Gd-chelates were 
characterized by their longitudinal relaxivity, r1 = (Δ1/T1)/[CA], where Δ1/T1 is the 
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change in relaxation rate (s-1) of solvent water protons upon addition of contrast agent, 
[CA] at mM concentration.11 Figure 3.8 shows T1 relaxation times for Gd(DTPA)2- and 
Gd(DTPA-BMA) in the absence and presence of HSAF (Gd-to-HSAF subunit ratio = 1), 
which were determined using a Bruker mq60 MR relaxometer operating at 1.41 T (60 
MHz). As a useful comparison, T1 values were measured in the presence of the same 
concentration of HSA (Figure 3.9), which is known to interact only very weakly with 
Gd(DTPA)2- and Gd(DTPA-BMA).11,33 Linear fitting of the data gave the r1 values 
shown in Table 3.2. The results with these undialyzed samples indicated slightly more 
association of Gd(DTPA)2- with HSAF than with HSA, but much less binding than that 
found for Gd(DTPA-BMA) and HSAF. 
Relaxivity measurements were also used to probe dialyzed samples of apoferritin 
bound to Gd(DTPA-BMA). Linear fitting of T1 versus Gd3+ concentration (Figure 3.10) 
gave the “Gd-bound” r1 values shown in Table 3.2. The r1 values of Gd(DTPA-BMA) 
increased more than 20-fold when bound to either horse spleen or human H apoferritin 
(77.8 and 73.4 mM-1 s-1), as compared to its unbound form (3.4 mM-1 s-1). The Gd-chelate 
MS-325 was shown previously to increase proton relaxivity ninefold upon binding HSA 
(r1 = 51 mM-1 s-1), due to the increase in the rotational correlation time (τR) of the Gd-
chelate upon binding to protein (10.1 ns bound vs. 115 ps free).34 Here, the even slower 
rotation of 12-nm diameter apoferritin (τR ≈ 200 ns)35 increased the relaxivity of protein-
bound Gd(DTPA-BMA).  
The design of high-relaxivity gadolinium agents has been the focus of considerable 
research,11,34 based on the potential for improving contrast in MRI. It is noteworthy that 
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the large relaxivities measured for apoferritin-Gd(DTPA-BMA) samples have been rarely 
seen in other synthetic or biological Gd3+ conjugates. Tsourkas and co-workers increased 
Gd payloads by first conjugating Gd-chelates to dendrimers and then either encapsulating 
dendrimers within polymersomes36,37 or cross-linking dendrimers to form nanoclusters,38 
and achieved relaxivities as high as 12.3 mM-1 s-1. In a few cases, relaxivities greater than 
100 mM-1 s-1 per Gd have been posited in the literature.39,40 A relevant biological 
example comes from Douglas et al. who covalently bound Gd3+ to cowpea chlorotic 
mottle virus and recorded the highest relaxivity values (~ 200 mM-1 s-1) for paramagnetic 
materials to date.39 In the present study, MRI data were collected for pure HSAF (5.3 
μM) as a control, for pure Gd(DTPA-BMA), and for HSAF-1.18 equiv Gd(DTPA-BMA), 
both containing 150 µM Gd3+. Figure 3.11 shows the T1 map. The binding of Gd(DTPA-
BMA) to HSAF caused a decrease in  T1 values and produced a higher-signal image. This 
MRI experiment confirms a method for increasing contrast by complexing Gd-chelates to 
apoferritin. 
The effect of Gd-chelate binding on iron oxidation and mineralization was studied with 
all four apoferritins. UV-Vis spectroscopy measured the increase in absorbance at 350 
nm immediately following the addition of 500 equiv Fe2+ to each apoferritin solution 
(0.33 μM) (Figure 3.12). Kinetics traces of the dialyzed apoferritin-Gd(DTPA)2- samples 
generally overlapped with those of pure apoferritin. One exception was the observation of 
enhanced rates of iron oxidation and mineralization with dialyzed HuHF-Gd(DTPA)2- 
samples. ICP-OES indicated less than 0.1 Gd per HuHF 24-mer, which was considered to 
be no Gd in this work. In contrast, the presence of Gd(DTPA-BMA) caused a slower rate 
85 
 
of iron oxidation in all apoferritins studied. One possible explanation is that Gd(DTPA-
BMA) obstructs the routes of Fe2+ uptake, for example by binding in the threefold 
channels of apoferritin. A second and concurrent possibility is that Gd(DTPA-BMA) 
inhibits iron oxidation and mineralization by disrupting the early recognition of Fe2+ 
inside apoferritin, e.g., at the di-iron ferroxidase sites that are contained in H-ferritin 
subunits. Support for the second explanation comes from the observation of least 
inhibition in HuLF (Figure 3.12C), and is consistent with less Gd binding to HuLF, as 
shown by ICP-OES. 
To investigate the possibility that Gd(DTPA-BMA) blocks Fe2+ uptake in apoferritin, 
we set out to determine whether the Gd-chelate binding to HSAF inhibits the subsequent 
binding of Tb3+. Tb3+ has been shown previously to provide a luminescent probe for 
measuring metal ion uptake by HSAF.41,42 In a different study, competition for Tb3+ 
binding sites in HSAF provided evidence of Cr(TREN) occupancy at the threefold 
pores.43  
Here, solutions of Tb3+ and HSAF, dialyzed HSAF-Gd(DTPA)2-, or HSAF-1.18 equiv 
Gd(DTPA-BMA) were stirred at 25 °C overnight; the amount of Tb3+ added ranged from 
1 to 8 equiv per HSAF. Unreacted Tb3+ was separated from the apoferritin-Tb3+ samples 
by centrifugal filtration (100 kDa exclusion size). A control experiment was made by 
mixing Tb3+ in protein-free solution. Filtrate (2.6 mL) that contained only reacted Tb3+ 
was mixed with 1,10-phenanthroline (phen, 0.4 mL) in a 4 : 1 phen-to-Tb3+ ratio, 
producing quantifiable luminescence from the Tb3+-phen complex. Figure 3.13 presents 
Tb3+-phen luminescence as a function of the total Tb3+ added per HSAF subunit. The 
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slope of luminescence intensity for the different filtrate solutions is equal to that of the 
control solution, beginning at approximately 3 equiv of Tb3+ per HSAF subunit, which 
indicated that saturation of all Tb3+ binding sites was achieved. No difference was 
observed between the filtrate solutions originating from the different HSAF samples, 
confirming that sites occupied by Gd(DTPA-BMA) did not inhibit the subsequent 
binding of Tb3+. We conclude that Gd(DTPA-BMA) must bind sites outside the Tb3+-
delineated route of metal uptake, which includes the threefold pores.  
To investigate more directly whether Gd(DTPA-BMA) competes with iron for the 
apoferritin ferroxidase sites, a ferric intermediate test was performed. Previous 
investigation of FHF revealed a millisecond-timescale diferric peroxo intermediate 
formed in the iron oxidation process. This diferric intermediate is much longer-lived in 
FHF-L134P,44-46 which allows convenient spectroscopic monitoring. In our study, just 48 
equiv Fe2+ (two per protein subunit) were added in order to determine whether the H-
chain-specific diferric intermediate was formed during iron oxidation. An absorption 
band at ca. 525 nm was immediately recorded upon mixing FHF-L134P (1.0 μM) and 
Fe2+ (Figure 3.14A). This absorbance feature was not observed after mixing FHF-L134P-
0.68 equiv Gd(DTPA-BMA) and Fe2+ (Figure 3.14B). Furthermore, the presence of 
Gd(DTPA-BMA) delayed the rise in UV absorption. This was in agreement with the 
prior 500 equiv Fe2+ per apoferritin ferroxidase experiments (Figure 3.12), further 
evidencing that Gd(DTPA-BMA) inhibits iron mineralization. Previously, loading 
Cr(TREN) into FHF-L134P slowed formation of the ferric intermediate, even with less 
than one Cr(TREN) bound per subunit.4 We conclude, as Theil et al. had in the study, that 
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the binding site(s) of Gd(DTPA-BMA) should be at or near the ferroxidase centers of the 
H-chain subunit. Efforts are underway to characterize crystallographically the apoferritin-
bound Gd species. 
 
4. Conclusions 
In summary, we studied the interaction of four apoferritins with two widely used 
gadolinium MRI contrast agents. The non-ionic Gd(DTPA-BMA) was found to bind 
apoferritins in varying stoichiometries, in some cases above one Gd3+ complex per 
subunit, while the anionic Gd(DTPA)2- was not detectable in apoferritin solutions after 
dialysis. Remarkable relaxivity enhancement and iron mineralization inhibition were 
observed as a result of Gd(DTPA-BMA) binding to apoferritins. This study suggests 
possible ferritin-Gd(DTPA-BMA) interactions and dysregulation of iron storage in vivo, 
which will require further investigation, and may be particularly relevant in patients with 
impaired kidney function who clear the Gd agent slowly from the body.  
 
5. Future Directions 
This chapter reports the binding interactions between four different apoferritins and 
two commonly employed gadolinium chelates. The use of apoferritin is particularly 
helpful for determining the binding site(s) of gadolinium chelates. Results show that the 
binding site(s) of Gd(DTPA-BMA) should be at or near the ferroxidase centers of the H-
chain subunit. However, in the human body, holoferritin (loaded with iron) is the 
predominant form of the protein. Therefore, the study of the binding interactions between 
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holoferritins and gadolinium chelates will be a new research direction with biomedical 
implications. 
As a preliminary investigation, I chose horse spleen ferritin (HSF) as the holoferritin 
and Gd(DTPA-BMA) as the gadolinium chelate. HSF-Gd(DTPA-BMA) complex was 
prepared following essentially the same procedure as described for the apoferritin 
experiments. After proper dialysis, the Gd and protein concentrations of this sample were 
determined. The data showed that 63.8 equiv of Gd(DTPA-BMA) were associated with 1 
equiv HSF, which is a much higher ratio than the 28.3 equiv Gd(DTPA-BMA) that were 
determined to bind HSAF. The reason for this higher ratio remains to be determined, but 
suggests that the Gd chelate may be interacting with ligands on the surface of the iron 
mineral. The effect of Gd(DTPA-BMA) binding on iron oxidation and mineralization 
was also studied. UV-Vis spectroscopy measured the increase in absorbance at 470 nm 
immediately following the addition of 500 equiv Fe2+ to HSF solution (1.0 μM) (Figure 
3.15). The absorption signal at 350 nm, which was used to monitor the kinetics in 
apoferritin experiments, was too noisy in HSF experiments. Therefore, 470 nm was used 
as the monitoring wavelength. 
The kinetics trace of HSF-Gd(DTPA-BMA) reacting with 500 equiv Fe2+  was nearly 
identical to that of pure HSF. It is noteworthy that sometimes the absorbance change 
measured by UV-Vis spectroscopy with HSF-Gd(DTPA-BMA) was slightly lower than 
pure HSF. Careful analysis revealed that this intensity difference started at t = 0. To 
calibrate this difference, the absorption intensities at t = 0 were set as zero as shown in 
Figure 3.15. Such a calibration is necessary in HSF experiments due to the strong 
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background absorption of the iron core. Future work will include human holoferritin and 
experiment on both Gd(DTPA)2- and Gd(DTPA-BMA). 
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Table 3.1. Differences in the protocols for synthesizing HuHF, HuLF, and FHF-L134P. 
________________________________________________________________________ 
    HuHF    HuLF   FHF-L134P 
________________________________________________________________________ 
broth (1 L)      tryptone: 10.0 g   tryptone: 10.0 g tryptone: 10.0 g 
       yeast extract: 5.0 g   yeast extract: 5.0 g yeast extract: 5.0 g 
    NaCl: 10.0 g   NaCl: 10.0 g  NaCl: 10.0 g 
    1 M NaOH: 1.0 mL   1 M NaOH: 1.0 mL 1 M NaOH: 5.0 mL 
         sorbitol: 182.2 g 
         betaine: 0.293 g 
incubation time     ~ 3 h    ~ 4 h   ~ 8 h 
needed to reach 
O.D.600 nm = 0.9~1.0 
inducing agent     IPTGa    3-IAAb  IPTGa 
and amount      240 mg/L    50 mg/L  240 mg/L 
incubation time     4 h     overnight  overnight 
and temperature     37 °C    20 °C   20 °C 
________________________________________________________________________ 
a: IPTG = isopropyl β-D-1-thiogalactopyranoside 
b: 3-IAA = 3β-indoleacrylic acid 
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Table 3.2. Summary of r1 values. 
________________________________________________________________________ 
Gd(DTPA)2-  Gd(DTPA-BMA) 
________________________________________________________________________ 
undialyzed samples 
pure Gd chelates   2.9 mM-1 s-1  3.4 mM-1 s-1 
HSA-Gd chelates   2.9 mM-1 s-1  3.7 mM-1 s-1 
HSAF-Gd chelates   3.2 mM-1 s-1  12.1 mM-1 s-1 
dialyzed samples 
HSAF-1.18 equiv Gd(DTPA-BMA)    77.8 mM-1 s-1      
HuHF-0.37 equiv Gd(DTPA-BMA)    73.4 mM-1 s-1      
________________________________________________________________________ 
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Figure 3.1. Molecular structures of Gd(DTPA)2- and Gd(DTPA-BMA). 
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Figure 3.2. Sclerotic plaque with calcinosis on the back arm of the patient. 
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Figure 3.3. FPLC elution traces of HuHF (red), HuLF (black), and FHF-L134P (blue) 
monitoring absorbance at 280 nm. 
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Figure 3.4. Preparation of apoferritin-Gd-chelate complexes. 
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Figure 3.5. Far-UV circular dichroism measurements for samples (A) HSAF and (B) 
HuHF. 
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Figure 3.6. Tryptophan fluorescence measurements for samples (A) HSAF and (B) 
HuHF.  
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Figure 3.7. Binding stoichiometry of Gd-chelates to HSAF vs. number equiv Gd added, 
after 24-h dialysis. 
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Figure 3.8. Relaxivity measurements for (A) pure Gd(DTPA)2-, (B) pure Gd(DTPA-
BMA), (C) undialyzed HSAF-Gd(DTPA)2-, and (D) undialyzed HSAF-Gd(DTPA-BMA). 
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Figure 3.9. Relaxivity measurements for (A) undialyzed HSA-Gd(DTPA)2- and (B) 
undialyzed HSA-Gd(DTPA-BMA). 
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Figure 3.10. Relaxivity measurements for (A) HSAF-1.18 equiv Gd(DTPA-BMA) and 
(B) HuHF-0.37 equiv Gd(DTPA-BMA). 
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   sample:                 HSAF             Gd(DTPA-BMA)   HSAF-1.18 equiv Gd(DTPA-BMA) 
 T1 values:              1424 ms                     720 ms                      307 ms   
 
 
 
 
 
 
 
 
 
 
Figure 3.11. T1 map of pure HSAF (5.3 μM), pure Gd(DTPA-BMA) (150 μM), and 
HSAF-1.18 equiv Gd(DTPA-BMA) ([Gd3+] = 150 μM).  
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Figure 3.12. Kinetics of iron oxidation and mineralization upon addition of 500 equiv 
Fe2+ to four apoferritins (A-D). Dotted line (black), Fe2+; dashed line (red), apoferritin + 
Fe2+; solid line (green), dialyzed apoferritin-Gd(DTPA)2- + Fe2+; dashed dotted line 
(blue), apoferritin-x equiv Gd(DTPA-BMA) + Fe2+, where x = 1.18 in (A), 0.37 in (B), 
0.22 in (C), and 0.68 in (D).  
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Figure 3.13. Luminescence measured upon addition of 1,10-phenanthroline to samples 
containing varying amounts of Tb3+ per HSAF subunit. Excitation wavelength: 290 nm. 
 (green), Tb3+;  (cyan), HSAF + Tb3+; | (red), dialyzed HSAF-Gd(DTPA)2- + Tb3+; — 
(black), HSAF-1.18 equiv Gd(DTPA-BMA) + Tb3+.  
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Figure 3.14. Absorption spectra on adding Fe2+ to (A) FHF-L134P or (B) FHF-L134P-
0.68 equiv Gd(DTPA-BMA). 
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Figure 3.15. Kinetics of iron oxidation and mineralization upon addition of 500 equiv 
Fe2+ to HSF. 
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Appendix 1: Developing Strategies for Creating Ferritin-Gold 
Nanoparticle Dimers Using Streptavidin-Biotin Junctions 
 
Gold nanoparticle dimers have shown important applications in both physical and 
biological sciences.1,2 In physical sciences, gold nanoparticle dimers are of special 
interest because of their application as substrates in surface-enhanced Raman 
spectroscopy (SERS).1 This enhancement effect is attributed to the random formation of 
localized plasmons at the junctions between nanoparticles, giving rise to large 
enhancements that enable SERS detection at or near single-molecule sensitivity.3 
Theoretical investigation by Nordlander et al. showed that a pair of closely spaced 
nanoparticles supports dimer plasmons that can be viewed as the bonding and 
antibonding combinations, i.e., hybridization of the individual nanoparticle plasmons, in 
analogy with eigenstates of homonuclear diatomic molecules.4 In biological sciences, the 
distance change between two gold nanoparticles can be used to monitor biological 
processes in real time.2 Alivisatos and co-workers proposed pairs of gold nanoparticles as 
“plasmon rulers” based on the dependence of their light scattering on the interparticle 
distance.5 In their later work, such a plasmon ruler has been used to study the cleavage of 
DNA by the restriction enzyme EcoRV at the single-molecule level.2 Ringler et al. 
synthesized nanoparticle dimers by linking biotin-functionalized gold nanoparticles with 
streptavidin, and consequently changed optically the distance between two gold 
nanoparticles by Raman-induced motion of the linker protein.6 
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During the past several years, preparing nanoparticle dimers using DNA as the linker 
has witnessed substantial progress.7-9 Alivisatos and co-workers have succeeded in 
putting a fixed number of thiolated ss-DNA molecules onto the surface of a gold 
nanoparticle. Various structures, including DNA-linked nanoparticle dimers and pyrimids, 
have been constructed following established techniques.7-9 However, when nanoparticle 
dimers are prepared using methods other than the above DNA conjugation method, 
several issues are revealed, and need to be summarized to benefit future investigation. 
Issue 1: there are no specific binding sites on the nanoparticle monomers. In the paper 
published by Feldheim and co-workers, nanoparticle dimers were formed by using 
citrate-capped gold nanoparticles and sulfur-containing phenylacetylene oligomers as the 
linkers.10 Because there are no specific binding sites on the gold nanoparticles, the 
mixing of nanoparticles with linker molecules could easily lead to the formation of 
aggregates. To avoid forming aggregates, the authors accomplished the dimer preparation 
by producing a locally high concentration of gold nanoparticles with respect to the linkers. 
As a result, a large amount of monomers were mixed with dimers (monomer-to-dimer 
ratio = 2.3 : 1).  
Issue 2: the preparation of nanoparticle dimers was not accomplished in a single phase. 
To incorporate specific binding sites in the nanoparticles for dimer preparation, various 
groups have introduced the idea of using the combination of two phases to mediate the 
nanoparticle functionalization. Zhang and co-workers took advantage of a toluene-water 
interface to attach tiopronin to one side of gold nanoparticles, and then prepared dimers 
using ethylenediamine as the linker.11 Sardar et al. asymmetrically functionalized gold 
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nanoparticle via a solid-phase approach and then synthesized dimers in a solution 
phase.12 The involvement of organic phase or solid phase not only makes the reaction 
system complicated, but also limits the use of biomaterials in these samples. 
DNA itself lacks various functional groups. To explore the diversity of nanoparticle 
synthesis, we are interested in preparing nanoparticle dimers using a non-DNA-related 
method. Systems that can solve the above two problems will (1) have specific binding 
sites on the nanoparticle monomers, and (2) accomplish the nanoparticle dimer 
preparation in a single phase. Here, we choose a particular thermophilic ferritin that has 
the capability of disassembling at low salt concentrations and reassembling in the 
presence of gold nanoparticles (Figure A1.1).13 We plan to label each ferritin with two 
biotins and use streptavidin to link two ferritins together.  
The wt thermophilic ferritin (hereafter abbreviated as T0) used in this work is from the 
hyperthermophilic Archaeon Archaeoglobus fulgidus.14 To attach biotins to T0, the 
commonly used method is to perform a biotinylation reaction with the cysteines of the 
protein. However, there are no native cysteines anywhere (surface, interior, etc.) in T0. 
Therefore, the cysteine should be introduced to T0 via site-directed mutagenesis. In fact, 
having no native cysteines in T0 serves as an advantage, because in this case Cys labeling 
can only occur at the engineered sites. After careful examination of the crystal structure 
of T0, we decided to engineer mutated ferritin containing an S80C mutation (hereafter 
abbreviated as T1eC) due to two reasons: (1) the S80C mutation site, as shown in Figure 
A1.2A, is surface exposed providing convenience in Cys labeling; (2) the S80C mutation 
site is in a loop of the 4-helix bundle, which can largely minimize the effect of mutation 
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on the subsequent subunit assembly. Figures A1.2A, A1.2B, and A1.2C present the 
structures of T1eC dimer, the biotinylation reagent, and streptavidin complexed with four 
biotins, respectively, together with relevant distance information. Figure A1.2D reveals 
that our design is geometrically feasible. 
In our design as illustrated in Figure A1.3, T1eC subunits are first labeled with biotins 
and are then mixed with T0 subunits to encapsulate gold nanoparticles. Streptavidin is a 
tetrameric protein that is remarkable for its ability to bind up four biotins with unusually 
high affinity (dissociation constant KD = 10-15 M).15 In this work, streptavidin is used to 
link two ferritins together. 
T0 can be isolated from E. coli in high yield, whereas the production efficiency of 
T1eC was much lower. Therefore in this work, I first tried to optimize the conditions for 
growing T1eC. Two main factors that may affect the protein growth were examined: (i) 
incubation time after adding IPTG; (ii) selection of bacterial colonies. To address (i), four 
incubation times (2, 3, 4, and 5 hours) were tested. Running gels revealed that 4-hour 
incubation time gave the best results. In (ii), different colonies from the same agar plate 
were picked for protein growth. By running PAGE gels, it was found that the variation of 
colonies had a profound influence on protein production. Figure A1.4 shows the effect of 
colony on protein production. Besides two protein ladders, six protein lanes are shown in 
this figure; the left three correspond to three flasks of LB broth solution right before 
adding IPTG, while the right three correspond to the solution in the same flasks 4 hours 
after adding IPTG. Although three colonies were grown in the same agar plate, different 
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colonies exhibited distinct protein production capability. In this work, only the medium 
that contained the largest amount of protein was used in the protein synthesis. 
T1eC subunits were conjugated to the maleimide-PEG2-biotin linkers at the S80C 
mutation site. The assembly of T1eC subunits and T0 subunits around 10-nm gold 
nanoparticles was done using a protocol developed by Swift et al.13 Biotin-labeled gold 
nanoparticles were mixed with streptavidin in the ratio of 2:1. A control experiment 
without the use of gold nanoparticles was also done. T1eC subunits and T0 subunits in 
the 1:11 ratio were mixed in the high salt solution. Subsequently, biotin-labeled 
apoferritin and streptavidin were mixed in the 2:1 ratio. 
An attempt of purifying nanoparticle dimers by FPLC using a Superdex 200 10/300 
size exclusion column was made. However, these ferritin-encapsulated gold nanoparticles 
stuck to the packing material at the top of the column. Therefore, during the time I carried 
out these experiments, samples without FPLC purification were used in following TEM 
study. But it is noteworthy that later my colleagues found that stirring at room 
temperature for 48 h could be a way alternative to the thermocycling protocol for the 
assembly of thermophilic ferritin subunits around gold nanoparticles; more importantly, 
these gold nanoparticles can pass the FPLC column. This implies the likelihood that gold 
nanoparticles were exposed or protein was denatured in the thermocycling process. 
TEM images of gold nanoparticle dimers and apoferritin dimers are shown in Figures 
A1.5A and A1.5B, respectively. Results support the effectiveness of using streptavidin to 
link two biotin-labeled ferritins. However, examination of the whole TEM grid revealed 
the presence of both the nanoparticle dimers and unreacted nanoparticle monomers. This 
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implies that the production efficiency of the nanoparticle dimers from monomers needs to 
be improved. Plans for further experiments on this project will include the use of 5-nm 
gold nanoparticles as the metal core during the assembly of thermophilic ferritins, and 
performing the assembly process via the room temperature stirring method. 
 
Experimental Section 
The pAF0834 vector containing T0 gene was provided by the laboratory of Dr. Eric 
Johnson at Caltech.14 The S80C mutant was engineered using the Stratagene QuikChange 
Site-Directed Mutagenesis Kit. The mutated cDNA was transformed into XL1-Blue 
Supercompetent E. coli cells (Stratagene) according to the manufacturer’s protocol. DNA 
was isolated using a QIAprep Spin Miniprep Kit (Qiagen). 
The plasmid for growing T1eC was transformed into BL21-CodonPlus (DE3)-RP 
competent cells of E. coli. Cell cultures were grown in 1-L LB broth supplemented with 
200 μg/mL ampicillin and incubated (37 °C, 225 rpm) until O.D.600nm was between 
0.9~1.0. Protein growth was induced by IPTG. After incubation at 37 °C, cells were 
harvested by centrifugation (5k rpm, 15 min) and resuspended in 40-mL buffer (10 mM 
Tris, 10 mM NaCl, pH 8.4, one protease inhibitor cocktail tablet). The cells were 
sonicated on ice (3 × 2 min) and then centrifuged (5 krpm, 10 min). The lysis supernatant 
was heat shocked (80 °C, 10 min) and ultracentrifuged (25 krpm, 90 min). The 
supernatant was purified on a 5 mL HiTrap FastFlow Q anion exchange column (GE 
Healthcare) (10 mM Tris, pH 8.4 with a 10 mM NaCl to 600 mM NaCl elution gradient; 
5 mL/min flow rate). The protein was equilibrated in 1 M NaCl for 24 h, concentrated 
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(100k MWCO Centricon, Millipore) and purified by size exclusion chromatography 
using a Superdex 200 10/300 GL column (GE Healthcare) (20 mM sodium phosphate, 
800 mM NaCl, pH 7.6 buffer; 0.5 mL/min flow rate). 
Prior to conjugation, T1eC was dissolved in 20 mM sodium phosphate, 20 mM NaCl, 
pH 7.6 buffer for unfolding. Disulfide bonds were reduced using 5 mM TCEP for 30 
minutes at room temperature, followed by TCEP removal using a 10DG desalting column 
(20 mM sodium phosphate, 20 mM NaCl, pH 7.0 buffer). Biotin was conjugated to T1eC 
subunits via the reaction of maleimide with the mutated cysteine. The biotinylation 
reagent was added in 20-fold excess. To determine the biotin labeling efficiency, the 
Ellman’s Reagent (Pierce # 22582) was used. In a T1eC solution (87.0 μM calculated 
based on the subunits), the free –SH concentration was found to be 17.9 μM. The 
percentage of unreacted –SH is 17.9 μM / 87.0 μM = 20.6%. Thus the biotin labeling 
efficiency is ~80%. To After removing the excess biotinylation reagent, T1eC subunits 
(10 nM) and T0 subunits (110 nM) were mixed in the presence of 10-nm gold 
nanoparticles (10 nM). The reaction mixture was annealed with a thermal cycling 
program comprised of 50 cycles of 2.5 min periods at 55 °C followed by 12 min periods 
at 4 °C. Biotin-labeled ferritin-encapsulated gold nanoparticles were mixed with 
streptavidin in the ratio of 2:1. 
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Figure A1.1. Cartoon showing hyperthermophilic ferritin’s capability of disassembling at 
low salt concentrations and reassembling in the presence of gold nanoparticles.  
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(A) Structure of T1eC dimer 
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(C) Structure of streptavidin 
complexed with four biotins 
 
distance between adjacent 
biotin binding sites on 
streptavidin = 2.1 nm 
 
 
 
 
 
 
 
 
(D) Summary of the distance 
information 
 
Figure A1.2. Structures of (A) T1eC dimer, (B) the biotinylation reagent, and (C) 
streptavidin complexed with four biotins. (D) Summary of distance information. 
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Figure A1.3. Cartoon illustrations of the biotinylation reaction (top) and formation of the 
streptavidin-biotin complexation system (bottom). In these illustrations, an assumption 
that Cys remains solvent exposed after nanoparticle incorporation is made. 
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Figure A1.4. PAGE gel showing the effect of colony on protein production. 
Experimental conditions: voltage = 200 V; time = 35 min; stained by Coomassie. Lanes 1 
and 8: protein ladders; lanes 2~4: LB broth solution in three flasks right before adding 
IPTG; lanes 5~7: LB broth solution in the same three flasks 4 hours after adding IPTG. 
LB broth solution in 1.5-mL microcentrifuge tubes has been kept in 80 °C water bath for 
10 min before running the gel.  
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Figure A1.5. TEM images of (A) gold nanoparticle dimers (red circles) and (B) 
apoferritin dimers (red circles). 
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Appendix 2: DNA-Based Streptavidin-Biotin Complexation 
System 
 
There are two basic types of nanotechnological construction: (i) ‘top-down’ 
construction, where atoms or molecules are microscopically manipulated to form elegant 
patterns; and, (ii) ‘bottom-up’ construction, where molecules self-assemble in parallel 
steps as a function of their molecular recognition properties. As a chemically based self-
assembly system, double-stranded DNA plays a key role in bottom-up nanotechnology 
because of its attractive molecular recognition capability and well-predicted duplex 
conformation.1,2 These nanometer-scale DNA building blocks provide the foundation for 
a particular research field termed structural DNA nanotechnology -- building DNA 
nanoarchitectures from the molecular level for a broad range of applications from new 
materials to devices. 
Structural DNA nanotechnology was first introduced in 1982 when Seeman proposed 
the idea of combining the sticky-end cohesion and branched DNA junctions to make 
geometric objects and periodic two- or three-dimensional lattices.3 More specifically, he 
theoretically predicted the self-assembly of six-arm branched DNA junctions into an 
ordered three-dimensional lattice. Later Seeman experimentally constructed such an 
object topologically equivalent to a cube.4 A general rule of the sequence design for the 
DNA building blocks is to minimize the sequence symmetry in the branched structure to 
avoid possible undesired pairing between participating strands and mobility of the 
junction points. Also, the DNA assemblies are based on the precise 1:1 association 
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between the strands involved, thus elaborate control of the purity and the relative 
stoichiometry of the strands are required to ensure a high yield of the desired assembled 
structure. 
Addressing functional groups on DNA nanostructures has been a burgeoning research 
area in structural DNA nanotechnology. Incorporating molecular components in the DNA 
motif is necessary so that the DNA nanostructure can serve as a template for assembling 
secondary components. A variety of methods have been used to attach molecules to 
specific building blocks, or tiles, in the DNA nanostructure. These methods include the 
incorporation of an additional double-stranded DNA hairpin which projects 
perpendicularly from the plane of the array,5,6 the use of biotin-labeled DNA to bind 
streptavidin,5,7 the use of biotin-labeled polyamides to bind streptavidin,8,9 the 
conjugation of DNA to gold nanoparticles,10,11 the insertion of the thrombin-binding 
aptamer and subsequent binding of thrombin,12 the  insertion of DNA aptamers that can 
be recognized by single-chain antibodies,13 and the recognition of a DNA-peptide fusion 
by an antibody.14 
It should be noted that DNA nanostructures are prone to dissociation as a result of the 
change of the solution condition, including variation of the media and increase in 
temperature. We aim at enhancing the stability of DNA nanostructure in this contribution. 
We borrow the idea of incorporating molecular components in the DNA motif and 
thereby introduce a streptavidin-biotin complexation unit to our DNA nanostructure. As a 
prototypal study, a DNA complex featuring a grid structure is chosen. 
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The construction of the nanogrid is the basis of this work. LaBean and co-workers 
designed and constructed a two-dimensional DNA nanogrid structure, which was 
composed of nine strands, with one strand participating in all four junctions.7 This work 
inspired Mao and co-workers to develop the concept of “sequence symmetry”. Utilizing 
the fourfold symmetry of cross-shaped tiles, they provided a new method of designing 
symmetric tile motifs.15 Sequence symmetry reduces the number of unique DNA strands 
needed, thus minimizing both cost and experimental errors. Sequence symmetry also 
helps to minimize the required unique sequence space, and thus greatly simplifies the 
sequence design. In our work, the DNA nanogrid was constructed following Mao’s 
design method.  
Figure A2.1 depicts the structure of the DNA nanogrids, which are two-dimensional 
and are composed of repeating DNA tiles. The red, yellow, and green strands in this 
figure correspond to strands i, ii, and iii, respectively (see Experimental Section for the 
sequences). Bridging these DNA tiles relies on the designed 5′-end (CGCG) and 3’-end 
(CATG) in iii. In this bridging mode, four biotin molecules (designed in strand iii) reside 
at each splint. Therefore, when the streptavidin is added after the formation of the grid, 
two streptavidin molecules are expected to bind to each splint via a two-biotin-one-
streptavidin binding mode. 
Figure A2.2 shows the AFM images of the DNA nanogrids and streptavidin-bound 
DNA nanogrids. To test if such a design can truly increase the binding strength of the 
splint and thus enhance the whole stability of the DNA nanogrid, two tests are performed, 
namely, gel test and melting temperature test. 
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A crucial point in the stability test is to examine the DNA nanogrid before and after the 
splints dissociate. To perform an important control experiment, one more DNA strand 
was also used as a replacement of iii. Designated as iv, its sequence is 5′-/biotin/CGT 
TAC CGT GTG GTT GCA TAG T/biotin/-3′. When using iv instead of iii, only discrete 
DNA tiles are formed, and its property should be intrinsically comparable to the grid 
dissociated at the splint sites. Figure A2.3 shows result from an agarose gel test. It is 
apparent that the splints dissociated when running the gel (lane 3). But when biotins were 
bound with streptavidin, the DNA nanogrid was still held up and behaved as a high 
molecular weight species (lane 4).  
Figure A2.4A shows the results from melting temperature measurement; Figure A2.4B 
is the first derivative analysis of the data in Figure A2.4A. It clearly reveals that the 
splints in the grid dissociated at ca. 52 °C (curve 3), while no dissociation was observed 
at this temperature when the grid is bound with streptavidin (curve 4). The discrete DNA 
tiles were dissociated beyond 60 °C in all four cases. 
Both gel test and melting temperature test support that the stability of the DNA 
nanogrids can be improved after streptavidin complexation. A high resolution AFM 
image of streptavidin-bound DNA nanogrids is needed to publish this work. Future 
applications of this DNA nanogrid include the use of this material as the substrate in 
photo activation light microscopy and on solid-supported fluid membrane surfaces to 
probe cell-substrate interactions. 
 
Experimental Section 
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All oligonucleotides were purchased from IDT, Inc. and purified by denaturing PAGE. 
Strand i: 5′-AGG CAC CAT CGT AGG TTT TCT TGC CAG GCA CCA TCG TAG 
GTT TTC TTG CCA GGC ACC ATC GTA GGT TTT CTT GCC AGG CAC CAT CGT 
AGG TTT TCT TGC C-3′; strand ii: 5′-ACT ATG CAA CCT GCC TGG CAA GCC 
TAC GAT GGA CAC GGT AAC G-3′; strand iii: 5′-/biotin/CGC GCG TTA CCG TGT 
GGT TGC ATA GTC ATG/biotin/-3′; strand iv: 5′-/biotin/CGT TAC CGT GTG GTT 
GCA TAG T/biotin/-3′. 
To prepare the DNA nanogrids: strands i (1 μM), ii (4 μM), and iii (4 μM) were 
combined in Tris/acetate/EDTA/Mg2+ (TAE-Mg2+) buffer, which consisted of Tris (40 
mM, pH 8.0), CH3COOH (20 mM), EDTA (2 mM), and Mg(CH3COO)2 (12.5 mM). 
DNA nanogrids were formed by slowly cooling the DNA solution from 95 °C to 5 °C 
over 40 h. Solution containing DNA nanogrids was stored at 4 °C and samples were 
normally used within 24 hours. DNA nanogrid solution was slowly added to streptavidin 
TAE-Mg2+ solution at 4 °C. Streptavidin-bound DNA nanogrid solution was stored at 
4 °C and samples were normally used within 24 hours. 
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Figure A2.1. Illustration of the designed DNA nanogrids. The red, yellow, and green 
strands correspond to strands i, ii, and iii, respectively. 
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Figure A2.2. AFM images of (A) DNA nanogrids and (B) streptavidin-bound DNA 
nanogrids. 
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Figure A2.3. Agarose gel test. Lanes a and b are lane markers. The box on the right-hand 
side explains the materials loaded in lanes 1, 2, 3, and 4. Strand i: 5′-AGG CAC CAT 
CGT AGG TTT TCT TGC CAG GCA CCA TCG TAG GTT TTC TTG CCA GGC ACC 
ATC GTA GGT TTT CTT GCC AGG CAC CAT CGT AGG TTT TCT TGC C-3′; 
strand ii: 5′-ACT ATG CAA CCT GCC TGG CAA GCC TAC GAT GGA CAC GGT 
AAC G-3′; strand iii: 5′-/biotin/CGC GCG TTA CCG TGT GGT TGC ATA GTC 
ATG/biotin/-3′; strand iv: 5′-/biotin/CGT TAC CGT GTG GTT GCA TAG T/biotin/-3′. 
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Figure A2.4. (A) Melting temperature measurement result. (B) First derivative analysis 
of the data in (A). In (A) and (B), the curves 1- 4 correspond to the same materials loaded 
in lanes 1-4 as specified in the caption of Figure A2.3. 
